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ABSTRACT 
 
Neurodegenerative disorders are debilitating conditions characterised by 
progressive dysfunction and death of neuronal cells by means of apoptosis, necrosis or 
autophagic degeneration. These conditions include, amongst others: Parkinson’s 
disease (PD), Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS), and 
Huntington’s disease (HD). Amidst the proposed mechanisms of neurodegeneration, 
the effects of excitotoxicity via glutamate receptor stimulation on neuronal cells are 
prominent. Excessive extracellular glutamate and/or membrane depolarisation 
activates N-methyl-D-aspartate (NMDA) receptors and voltage-gated calcium 
channels (VGCC). These activations result in increased intracellular calcium ions and 
calcium overload that subsequently lead to neuronal cell death. Phencyclidine (PCP) 
and dizolcipine (MK-801) have proven to noncompetitively block NMDA receptors 
and in this process slow down the degenerative cascade, but are marked by 
undesirable side effects. Uncompetitive blockers such as memantine and amantadine 
proved to be neuroprotective with fewer side effects and are approved for clinical use 
against neurodegenerative disorders. This has led to the development of structurally 
related polycyclic molecules such as NPG1-01, a closed polycyclic cage, which 
exhibit neuroprotective properties through NMDA receptor and VGCC inhibitions 
with lower side effect profile.  
Tricycloundecane derivatives which are open cage or rearranged polycyclic 
cage moieties have also been synthesised, but their potential medicinal use have not 
been explored. This study focused on the synthesis of a series of novel 
tricycloundecane derivatives and evaluation of these compounds for neuroprotection 
using the fluorescent ratiometric calcium assay that indicates the ability of the test 
compounds to inhibit NMDA receptors and VGCC. The cycloaddition reaction 
between p-benzoquinone and monomerised dicyclopentadiene yielded tricycloundeca-
4,9-diene-3,6-dione which was used as the base structure and further derivatised. 
These derivatives were conjugated with benzylamine to form a series of imines and 
amines. A total of 10 compounds were synthesised for evaluation of inhibition of 
calcium influx through NMDA receptor channels and voltage-gated calcium channels. 
The structures were confirmed using NMR, IR and MS. On the proton NMR, the 
characteristic AB-quartet system was observed in the region of 1-2 ppm for all the 
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compounds and the aromatic moiety was observed between 6.5-7.5 ppm for the novel 
polycyclic amines. These, with other functional groups, were used to confirm the 
individual structures.  
In the NMDA receptor inhibition assay, MK-801, memantine and NGP1-01 
were used as reference compounds and all showed statistically significant (p < 0.05) 
NMDA receptor inhibitory activity of 97.47%, 57.90% and 57.20% respectively at a 
100 µM concentration. Significant inhibition were observed for compound 2 (78.00%) 
and 3 (96.07%). The highest inhibitory activity (p < 0.05) was observed with 
compound 7, which exceeded the inhibitory activity of MK-801 in this assay. In the 
VGCC inhibition assay, nimodipine, amantadine and NGP1-01 were used as the 
reference compounds. Nimodipine and NGP1-01 showed statistical significant VGCC 
inhibition of 90.19% and 25.63% respectively at a 100 µM concentration. Compound 
6 (34.03%), 7 (38.07%) and 10 (40.33%) showed statistically significant (p < 0.05) 
VGCC inhibitory activity compared to NGP1-01 (25.63%). These compounds (2, 3, 6, 
7 and 10) demonstrated potential ability to attenuate calcium influx through NMDA 
receptor and/or VGCC. Thus, potential mono- or dual-functional neuroprotective 
activities including inhibition of NMDA receptors and/or voltage-gated calcium 
channels were observed for these compounds. 
The potential NMDA receptor and/or VGCC inhibitory activities of the 
tricycloundecane derivatives (2, 3, 6, 7, and 10) were demonstrated in this study. 
However, the true potential benefit as neuroprotective agents and safety in patients is 
yet to be established. The compounds could serve as lead structures for the 
development of novel neuroprotective drugs. 
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CHAPTER ONE 
Introduction 
1.1: Background 
Neurodegeneration is a process characterised by progressive loss of neuronal 
cells in the central nervous system. These cells undergo a cascade of events, 
enzymatic and non-enzymatic, that results in the death of neuronal cells and is the 
cause of various neurological disorders. These disorders, amidst others include; 
Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis 
(ALS) and Huntington’s disease (HD). The part of the brain affected differs in each 
disorder which is evident by their distinct symptoms (Farooqui & Farooqui, 2009; 
Galpern & Cudkowicz, 2007; Grosskreutz et al., 2010; Landrigan et al., 2005; Lee & 
Kim, 2006; Mayeux, 2003). The incidence of these disorders has increased in recent 
years and has led to a high demand in health care and social services causing a major 
burden to modern society (Fratiglioni & Qiu, 2009). 
Unfortunately, current drugs only offer symptomatic relief. Patients show 
improvement initially due to blunting of symptoms, but later deteriorate. This is 
evident in patients who are withdrawn from treatment as they perform no better than 
the placebo group soon after withdrawal (Geldenhuys et al., 2007). Although this 
approach does not halt the degenerative process, it is beneficial as increased life 
expectancy is observed in patients with no comorbidity. However, the overall cost, 
financial and human, reduces the quality of life. 
Countless studies have proposed distinct or overlapping factors, genetic and 
environmental, and molecular mechanisms that contributes to the pathogenesis of 
neurodegenerative disorders. Of these studies, none could establish a definite 
mechanism. However, it is generally believed that for each distinct neurodegenerative 
disorder, selectively vulnerable neuronal populations undergo cell death, which is 
either necrotic or apoptotic in nature, as a consequence of potentially interrelated 
processes. These processes include but are not limited to oxidative stress, 
excitotoxicity (Leist & Nicotera, 1998), RNA metabolism, mitochondria dysfunction 
(Moreira et al., 2012), and protein aggregation and propagation (Celsi et al., 2009; 
Mehta et al., 2013). Despite the vast knowledge and ongoing refinement in these basic 
insights, the pathogenesis of neurodegenerative disorders is still fragmented and 
poorly defined (Qureshi & Mehler, 2013). 
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Figure 1.1: Schematic representation of excitotoxic effects on cells. 
Amongst the established mechanisms of neurodegeneration, excitotoxic 
effects via glutamate receptor stimulation and calcium channel activation on neuronal 
cells are more prominent. These effects can either be primary or secondary. In 
primary or direct excitotoxicity, excessive extracellular glutamate over-activates N-
methyl-D-aspartate (NMDA) receptors to cause calcium influx and subsequently 
intracellular calcium overload (Lipton, 2007). Sensitive voltage-gated calcium 
channel (VGCC) activation also contributes to the calcium overload. This disruption 
in calcium homeostasis activates enzymes and generates free radicals that lead to cell 
death (figure 1.1). In secondary or indirect excitotoxicity, cell death results from 
normal glutamate receptor stimulation of a weakened postsynaptic neuron. An 
example of a weak postsynaptic neuron is one with low ATP production due to 
mitochondrial dysfunction. As a result, the ATP produced is incapable of producing 
energy required for normal physiological processes. The neuron becomes damaged 
and eventually dies. Indirect excitotoxicity can also occur in low-buffered cells. Anti-
apoptotic proteins such as B-cell lymphoma 2 (Bcl-2) or B-cell lymphoma extra large 
(Bcl-xL) facilitate the storage of intercellular calcium in the endoplasmic reticulum, 
thereby reducing mitochondrial loading and protecting neuronal cells from apoptotic 
death. Pathological conditions that enhances the activity of pro-apoptotic proteins 
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such as Bcl-2-associated X (Bax) or increases anti-apoptotic protein loss may 
antagonize this buffer-effect and promote apoptosis (Celsi et al., 2009; Ferdek et al., 
2012; Bonneau et al., 2013; figure 1.2). In both forms of excitotoxicity, glutamatergic 
neurotransmission and calcium influx plays a crucial role in cell death (Fan and 
Raymond, 2007; Gardoni & Di Luca, 2006; Haddad, 2005; Lau and Tymianski, 2010; 
Van Damme et al., 2003; Van Den Bosch et al., 2006). Therefore minimising calcium 
entry into neuronal cells without interfering with normal neuronal calcium 
homeostasis is vital in ameliorating neurological diseases. 
 
 
Normal physiological condition   Indirect excitotoxicity 
Figure 1.2: Schematic illustration of indirect excitotoxicity in low buffered cell (Taken from 
Wikispaces, 20 June 2013). 
It is proposed that antagonising NMDA receptors and blocking calcium 
channels in neuronal cells will be of therapeutic value by halting or reducing 
excitotoxicity, an essential process in neurodegeneration. Although this therapeutic 
strategy is effective in preventing glutamate-mediated neurotoxicity, a competitive 
antagonist will halt NMDA receptor activities which are essential for normal 
physiological transmission in the brain (Chen & Lipton, 2006). Competitive NMDA 
receptor antagonist such as midafotel and selfotel have been developed but 
discontinued because of their dose-related psychotomimetic side effects (Sonkusare et 
al., 2005; Loscher & Schmidt, 2006). Uncompetitive antagonism, also known as 
open-channel blockers, is a more appealing strategy for therapeutic intervention 
during excessive NMDA receptor activation as this action of blockade requires prior 
activation of the receptor (Chen & Lipton, 2006). Some of these uncompetitive 
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NMDA receptor antagonists have shown effectiveness in many experimental animal 
models of neurodegenerative diseases and moved into clinical trials. However, the 
initial enthusiasm for this approach has diminished as these drugs exhibit significant 
adverse effect at therapeutic doses (Gardoni & Di Luca, 2006). Phencyclidine (PCP), 
ketamine and dizolcipine (MK-801) (figure 1.3) have shown to uncompetitively block 
NMDA receptors to reduce or halt the degenerative process, but are marked by 
undesirable side effects such as psychotomimetic effects and impaired motor 
functions (Kiss et al., 2005). This is attributed to the high affinity of these compounds 
for the NMDA receptors. Therefore, drugs with low adverse effect profiles that still 
retain neuroprotective activity by inhibiting NMDA receptors will be advantageous in 
the treatment of these neurodegenerative disorders.  
O
NH
NH
CH3
N
Phencyclidine (PCP) Ketamine
Dizolcipine (MK-801)
NH
CH3
O
Cl
NGP1-01
NH2
CH3
CH3
Memantine
NH2
Amantadine
Figure 1.3: Chemical structures of PCP, MK-801, ketamine and polycyclic derived molecules 
with neuroprotective effects.  
Although polycyclic cage derivatives such as memantine, amantadine and 
NGP1-01 (figure 1.3) have been of interest to chemists for more than 50 years, it is 
only recently that the medicinal potential thereof has been explored (Ito et al., 2007). 
This interest has led to the development of numerous cage derivatives with 
established and potential therapeutic effects. These compounds and derivatives 
thereof have shown to inhibit NMDA receptors and/or calcium channels and are thus 
candidates for neuroprotection. These polycyclic compounds are uncompetitive 
NMDA receptor inhibitors with established neuroprotective properties and a low side 
effect profile is observed. These properties make them a highly promising group for 
the development of new drugs. An example is memantine (figure 1.3), a derivative of 
amantadine. Unlike ketamine, memantine is clinically well tolerated owing to its low 
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affinity on NMDA receptors. It is believed to block excitotoxic effect while allowing 
normal glutamatergic transmission. Memantine mainly modulates NMDA receptors to 
prevent pathological overactivation of this receptor. It has been shown in various 
studies that memantine only block excessive NMDA receptor activity without 
disrupting normal neuronal activity (Lipton, 2004). This offers protection to neurons 
by preventing or slowing down cell death. Derivatives of memantine are under 
scrutiny and could exhibit a higher potency than memantine with greater 
neuroprotective properties (Lipton, 2004; Johnson & Kotermanski, 2006; Wenk, 
2007). Several pentacycloundecylamine derivatives have been developed and reported 
in literature to have neuroprotective properties. In addition to their neuroprotective 
abilities, they are also useful moieties to conjugate to existing structures or molecules, 
currently on the market or under development, for the purpose of improving their 
pharmacokinetic and pharmacodynamic profiles (Van der Schyf & Geldenhuys, 
2009). Polycyclic cages such NGP1-01, a closed cage molecule (figure 1.3), exhibits 
L-type voltage-gated calcium channel blockage and NMDA receptor inhibition. 
NGP1-01 was also shown to be more potent than other polycyclic cages, such as the 
adamantanes, due to its characteristic dual inhibitory mechanism in attenuating 
calcium entry. This distinct characteristic gives NGP1-01 an advantage over other 
potential neuroprotective compounds as a drug candidate in prophylaxis and effective 
treatment of acute and chronic neurodegenerative disorders (Van der Schyf & 
Youdim, 2009). Numerous derivatives of this cage molecule have been synthesized 
and have shown considerable NMDA receptor and calcium channel inhibitory 
properties (Malan et al., 2000; Geldenhuys et al., 2004; Mdzinarishvili et al., 2005) 
O
O
O
O
+
0 oC/4 hrs
p-benzoquinoneCyclopentadiene
O
O
UV/6 hrs
Acetone
tricycloundeca-4,9-diene-3,6-dione
 
Scheme 1.1: Synthesis of tricycloundeca-4,9-diene-3.6-dione and Cookson’s diketone cage 
(Diels & Alder, 1928; Cookson et al., 1964). 
Tricycloundecane (scheme 1.1), an open cage polycyclic molecule, derivatives 
have also been extensively synthesised but its use in medicinal chemistry has not been 
explored (Geldenhuys et al., 2011). A series of novel tricycloundecyl amine and imine 
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phenyl derivatives which are structurally similar to NGP1-01 (figure 1.4) will be 
developed and evaluated in this study for their neuroprotective properties. These 
novel derivatives are structurally similar to NGP1-01 and MK-801, and provide the 
possibility to develop another group of cage derivatives with potential NMDA 
receptor and VGCC inhibitory activities. Since these compounds are expected to have 
similar structure-activity relationships as NGP1-01, we envision that comparable or 
improved neuroprotective effects will be observed. 
O
O
O
O
OH
O
O
O
Br
O
N
O
NH
O
N
O
NH
O
O
NH
OH
O
NH
1 2 3 4
5
6
7 8
9 10
Figure 1.4: Compounds synthesised and evaluated in this study. 
1.2: Rational and aim of this study 
The NMDA receptors and VGCC have been recognised as the two major 
targets responsible for calcium overload in glutamate-mediated neurotoxicity 
(Mdzinarishvili et al., 2005). The increased intracellular calcium mediated by these 
channels subsequently result in neuronal cell death. With this in mind, we direct our 
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research focus to slowing down the neurodegenerative processes by targeting these 
major pathways. Maintaining calcium homeostasis by inhibiting these channels while 
ensuring normal glutamatergic transmission is essential in the neuronal recovery 
process or neuroprotection (Grobler et al., 2006). Uncompetitive NMDA receptor 
inhibitors (PCP, MK-801, ketamine and some polycyclic cage derivatives) and VGCC 
inhibitors (Nimodipine and NGP1-01) are known to reduce calcium influx mediated 
by excitotoxicity. This offers protection to neuronal cells. However, some of these 
compounds disrupt physiological processes and cause psychotomimetic side effects 
due to their high affinity for the NMDA receptors. Polycyclic cages such as 
memantine and NGP1-01 have demonstrated significant neuroprotective activities 
with low side effect profiles by inhibiting one or both pathways. The low side effects 
profile is attributed to their moderate affinity at the NMDA receptor binding site 
(Sonkusare et al., 2005). 
The vital role of these major pathways in calcium overload and the desire to 
diversify lead structures which inhibit these pathways justified the rationale for 
synthesising a series of novel tricycloundecane compounds that target these channels 
in order to maintain calcium homeostasis in neuronal cells. 
Because NMDA receptor and VGCC inhibitions had been shown to be useful 
in the treatment of neurodegenerative diseases,This aim of this study was to design 
and synthesise tricycloundecane derivatives, structurally similar to NGP1-01 and MK-
801, and evaluating these novel polycyclic cages as VGCC and NMDA receptor 
inhibitors. Once a final series of compounds were identified, they were synthesised, 
purified using conventional laboratory techniques and elucidated using infrared (IR) 
spectrometry, mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
spectrometry. 
The synthesised compounds were evaluated by measuring calcium influx 
through NMDA receptors and voltage-gated calcium channels into 
synaptoneurosomes using NMDA/glycine and KCl as stimulants, respectively. The 
fluorescent ratiometric indicator, Fura-2 AM and Synergy™ Mx Monochromator-
based Microplate Reader was used to evaluate the influence of test compounds on 
calcium influx after stimulant-induced depolarisation. All test compounds were 
screened at a 100 µM concentration. This study identified the potential NMDA and 
VGCC inhibitory activity of the tricycloundecane series.  
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1.3: Conclusion 
The disruption in calcium homeostasis mediated by excitotoxicity plays a 
major role in the neurodegenerative process. Drugs available in the market only offer 
symptomatic relief without halting the degenerative process. Maintaining calcium 
homeostasis through NMDA receptor and VGCC inhibitions is beneficial. We 
envision that the synthesised compounds will inhibit the NMDA receptor and VGCC, 
and exhibit a low side effect profile. This would add to the list of lead structures with 
potential neuroprotection properties and aid in the development of effective 
neuroprotective drugs.  
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CHAPTER TWO 
Literature review 
2.1: Neurodegeneration 
2.1.1: Neurodegenerative disorders 
Neurodegenerative disorders are debilitating diseases characterised by progressive 
dysfunction and death of neuronal cells (Jellinger, 2007). The cells affected either 
become necrotic or apoptotic, the two main forms of death in neurodegenerative 
disorders (Connor & Dragunow, 1998), although autophagic degeneration, an 
uncommon form of cell death, is also a possibility (Waldmeier, 2003; Puyal et al., 
2013). These forms differ morphologically and biochemically (Martin et al., 1998). 
These disorders, amongst others, include; Parkinson’s disease (PD), Alzheimer’s 
disease (AD), amyotrophic lateral sclerosis (ALS) (Bains & Shaw, 1997), and 
Huntington’s disease (HD) (Caraci et al., 2012; Connor & Dragunow, 1998; Galpern 
& Cudkowicz, 2007; Gilgun-Sherki et al., 2001; Marambaud et al., 2009; Nicholls & 
Budd, 1998; Parsons et al., 1999; Walker, 2007). This group of diseases has more to 
do with advancing age, environmental cues and/or dysfunctional immune system and 
less with host genetics (Kabanov & Gendelman, 2007). Each disease affects different 
parts of the brain of susceptible individuals and presents with distinct devastating 
symptoms that greatly reduce the patient’s quality of life. The dopaminergic neurons 
in the substantia nigra (SN) pars compacta of the brain are depleted in PD and 
deterioration of cortical neurons is a characteristic of AD (Landrigan et al. 2005). 
Pyramidal neurons in the motor cortex and associated corticospinal tracts are 
degenerated in ALS. Lower neurons in the brainstem nuclei and anterior horn of the 
spinal cord are also degenerated (Mayeux, 2003), which result into progressive 
muscle weakness, atrophy, and spasticity (Galpern & Cudkowicz, 2007; Grosskreutz 
et al., 2010). Neurons mainly in the striatum and other basal ganglia structures are lost 
in HD (Lee & Kim, 2006; Farooqui & Farooqui, 2009). These critical areas in the 
central nervous system (CNS) are responsible for coordination and cognitive 
functions. Defects in these vital areas have mental, social and physical implications 
that negatively influence the individual’s active life. 
2.1.2: Occurrence, incidence, and prevalence of neurodegenerative disorders 
  PD and AD are the most common neurodegenerative disorders (Calon & Cole, 
2007), and occur mainly in the elderly. The onset and peak of symptoms of these 
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diseases occur in the sixth decade of life (Landrigan et al., 2005; Barlow et al., 2007), 
with early occurrence suggesting the involvement of genetic and/or environmental 
factors and poor prognosis (Schmechel et al., 2006). Although risk increases with age, 
it is not a normal senescence. The duration of illness before death for PD and AD is 
between 2-20 years and 9 years respectively. In PD, higher incidence is noted in men 
than in women (Mayeux, 2003; Wooten et al., 2004). Relative to AD and PD, ALS 
and HD are rare, but fatal with no effective treatment (Mayeux, 2003). These 
disorders can manifest at anytime between infancy and senescence with significant 
increase in rate with age (Lee & Kim, 2006; Fratiglioni & Qiu, 2009; Mayeux, 2003).  
In ALS, the duration of illness from the onset of signs and symptoms, most times 
subtle, is 3 to 5 years (Bains & Shaw., 1997; Di matteo et al., 2007; Galpern & 
Cudkowicz, 2007). The prevalence and incidence rate of the aforementioned 
neurodegenerative disorders are outlined in table 2.1 (Farooqui & Farooqui, 2009). 
Not only are these disorders (AD, PD, HD and ALS) similar in their degenerative 
mechanism but also in risk factors (old age and positive family history). Onset is often 
subtle (Farooqui & Farooqui, 2009, Eriksen et al., 2008). 
Table 2.1: Prevalence (per 1000 people) and incidence (per 100000 persons-years) 
rates of neurodegenerative disorders (Fratiglioni & Qiu, 2009). 
Neurodegenerative 
disorders 
Ages range (in years) Prevalence per 
1000 people 
Incidence 
per 100000 
person-year 
Amyotrophic latera1 
sclerosis 
All ages 0.06 1.5-20 
Huntington’s disease All  ages 0.04 -0.10 0 
Parkinson’s disease ≥ 65 10- 20 100 – 180 
Alzheimer’s disease ≥ 65 40 - 80 1200 - 3000 
 
2.1.3:  Cost implications 
The costs of managing neurodegenerative diseases have increased over the 
years (Landrigan et al., 2005). This is due to the rapid increase in the number of 
individuals suffering from these disorders which has led to high demand for health 
care and social services (Fratiglioni & Qiu, 2009). In addition to the financial cost is 
the human cost of distress, sadness and despair, and reduction in overall quality of life 
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(Landrigan et al., 2005), thus a costly burden on modern society (Eriksen et al., 
2008). 
2.1.4:  Treatment of neurodegenerative disorders 
Most registered drugs available in the market only offer symptomatic relief 
without reducing or halting the degenerative process. At the onset of a symptomatic 
treatment, metrics of benefit initially show significant improvement compared to 
placebo but ultimately, a parallel rate of decline is seen with untreated patients. 
Typically then, patients withdrawn from treatment would perform no better than the 
placebo group soon after withdrawal, even though they initially benefited due to the 
blunting of symptoms. The effect derived from symptomatic treatment is beneficial 
but palliative. In stark contrast, disease-modifying agents would either arrest or slow 
the progression of the disease, resulting in an attenuated velocity of decline that 
diverges significantly from the placebo (Kennedy, 2007; Geldenhuys et al., 2011). 
2.2: Mechanism of neurodegeneration 
As pointed out earlier, neurodegenerative disorders share a common form or 
mechanism of degeneration or neuronal damage. The etiopathology of these disorders 
is extremely complex and heterogeneous (Geldenhuys et al., 2011). Genetic and 
environmental factors are the main initiators of the neurodegenerative process. 
Neuronal cells prone to degeneration either become apoptotic or necrotic depending 
on the extent of insult (Le Feuvre et al., 2002) and in some cases, these forms of death 
may overlap as an apoptotic cell may eventually become necrotic. 
2.2.1: Forms of neuronal death 
2.2.1.1: Apoptosis 
Apoptosis is an energy-dependent programmed cell death characterised by a 
cascade of enzymatic action with non-traumatic phagocytic clearance, that is, 
phagocytosis without inducing inflammatory response (Raffray & Cohen, 1997; Love, 
2003). Apoptosis is the most common form of neuronal cell death, however its 
involvement in normal aging remains controversial (Krantic et al., 2005). Apoptosis 
or programmed cell death (PCD) plays a major role in the normal growth and 
differentiation of organ systems in vertebrates and invertebrates. This PCD is 
responsible for matching neuronal populations to target size, and it is thought to be 
largely controlled by a limiting supply of target-derived trophic factors, but is also 
controlled by afferent stimulation (Martin et al., 1998). Two main pathways (intrinsic 
and extrinsic) lead to apoptotic neuronal cell death. The intrinsic pathway involves 
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mitochondrial damage due to reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), increased Ca
2+
 influx leading to excitotoxicity, hypoxia and UV 
exposure. This leads to cytochrome c release into the cytosol, with the subsequent 
formation of the apoptosome and the activation of effector caspases. The extrinsic 
pathway involves binding of a specific ligand to apoptotic initiating receptors of the 
tumour necrosis factor family, which induces activation of effector caspases (Artal-
Sanz & Tavernarakis, 2005; Waldmeier, 2003). 
 
Figure 2.1: Schematic illustration of an apoptotic event (Taken from Sigma-Aldrich, 24 June 
2012). 
Toxic agents such as detrimental free radicals, drugs and toxic chemicals 
interact with the cell (figure 2.1). These interactions lead to the formation of lesions 
on the cell surfaces. The cells sense the damage and initiate the repair process in non-
apoptotic cells. In apoptotic cells, the damage exceeds the repair capability of the cell 
leading to activation of caspases, products of proteolytic cleavage of procaspases 
(proenzymes), directly involved in apoptosis (Raffray & Cohen, 1997). These 
caspases are divided into two broad groups which are initiator caspases and effector 
caspases. The initiator caspases interact with the dead domains of other 
transmembranes and intracellular proteins involved in apoptosis initiation; via these 
interactions, a range of pro-apoptotic stimuli is transduced into proteolytic activity. At 
this stage, the cells have reached ‘a point of no return’. Activation of the apoptotic-
effector system, involving effector caspases, results in death of the cells. The effector 
caspases involved in the cleavage of cellular substrates that are directly responsible 
for most morphological and biochemical changes evolve in apoptosis. The substrates 
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inactivated by caspases include cytoskeletal proteins such as actin, α-fodrin, and 
gelsolin; structural nuclear protein such as lamins; DNA repair proteins such as DNA-
dependent protein kinase, and poly (ADP-ribose) polymerase (PARP); the anti-
apoptotic protein Bcl-2 and Bcl-xL; and the inhibitor of caspase-activated DNase. The 
enzymatic cleavage of inhibitors of caspase-activated DNase leads to the release of 
caspase-activated DNase, an enzyme that causes apoptotic cleavage of nuclear DNA. 
Although caspases is the main mediator for apoptosis, others include apoptotic 
inducing factor, a flavoprotein confined to the mitochondrial intermembrane space, 
endonucleases, and transglutaminase (Love, 2003). Apoptosis is more involved in 
scattered discrete cells with a lower injury level capable of initiating apoptotic 
response in comparison to necroses (Raffray & Cohen, 1997). 
2.2.1.2: Necrosis 
Necrosis, a relatively unordered process (Yanamadala & Friedlander, 2009), is 
the passive killing of a cell (Jellinger, 2007). In contrast to apoptosis, cells involved in 
necrosis are usually in large numbers or confluent volume and undergo extensive 
inflammatory response. Severe, sudden or high degree of injury results from 
detrimental agents and target cell interaction. This causes irreversible damage leading 
to homeostatic failure, ‘point of no return’. At this point, the cell loses its function and 
uncontrolled degradable enzymatic action leads to lysis and reactive inflammation 
(Raffray & Cohen, 1997).  
Cell death by necrosis exhibits rapid cell swelling and subsequent rupture of 
the plasma membrane, due to an inflammatory response, that usually induces 
substantial secondary cell damage in the surrounding tissues (Jellinger, 2007). 
Although the molecular mechanism that brings about necrotic death is not fully 
elucidated, experimental evidence indicates that necrosis of adult neurons is mediated 
by an increase in intracellular Ca
2+
 and is independent of caspases. Instead cytosolic 
calpains and spilled lysosomal cathepsins are the major players in necrotic neuronal 
death.  
Energy depletion is a potent trigger for necrosis. Acidification, a consequence 
of oxygen depletion, also plays an important role in necrotic neuronal death. Acidosis 
activates Ca
2+
-permeable acid sensing ion channels (ASIC) resulting in glutamate 
receptor-independent neuronal injury due to Ca
2+
 toxicity (Artal-Sanz & 
Tavernarakis, 2005). 
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2.2.2: Oxidative stress in neurodegeneration 
 Oxidative stress, a major cause of neurotoxicity, arises as a result of an 
imbalance in the production of detrimental free radicals and natural antioxidants, 
enzymatic and non-enzymatic, leading to oxidative damage to the cell and its 
constituents (Gilgun-Sherki et al., 2001; Crouch et al., 2008; Gonsette, 2008). The 
brain as a vital organ, although small in size, has a disproportionally high level of 
oxygen consumption mainly due to its high energy (ATP) demand. The centre for 
ATP production is the mitochondrial electron transport chain known as the 
powerhouse or engine of the cell (Sas et al., 2007; Crouch et al., 2008). This 
mitochondrial electron transport chain and its enzyme complexes form ROS, mostly 
via inhibition of one or more enzyme complexes leading to ineffective transfer of 
electrons to oxygen during oxidative ATP production (Crouch et al., 2008). The ROS 
include superoxide anion (02
·-
), hydrogen peroxide (H2O2), hydroperoxy radicals 
(
·
OOH), Hydroxy radical (
·
OH), Nitric oxide (NO
-
), and peroxynitrate (ONOO
-
) 
(Raffray & Cohen, 1997; Gilgun-Sherki et al., 2001; Gonsette, 2008). Reactive 
species such as 
·
OH, 02
·-
,
 ·
OOH and NO
- 
are free radicals while H2O2 and ONOO
-
 are 
molecules capable of generating free radicals through various chemical reactions 
(Gilgun-Sherki, 2001). β-Amyloid (Aβ) interaction with copper ions can also generate 
ROS. Aβ has the ability to reduce Cu (II) to Cu (I) to produce H2O2 as a by-product 
(Crouch et al., 2008). ROS are capable producing multiple of potentially lethal 
cellular effects, including ATP depletion, calcium influx elevation, and oxidation of 
glutathione, NADH, lipids, and macromolecular thiol, all of which contributes to the 
degeneration process (Raffray & Cohen, 1997). Cerebrovascular disorders are also 
capable of generating nitrogen and oxygen free radicals via a complex cascade of 
metabolic events (Qureshi et al., 2004). 
 Under physiological conditions, the ROS are counterbalanced by both natural 
enzymatic and non-enzymatic antioxidants (Gilgun-Sherki et al., 2001; Lobo et al., 
2010). At low levels, ROS function as signalling intermediates for the modulation of 
fundamental cellular activities such as growth and adaption responses (Farooqui & 
Farooqui, 2009). In pathological conditions such as inflammation or age-related 
neurodegeneration, high level of ROS are produced which overwhelm natural 
antioxidant defence, leading to oxidative stress (Gilgun-Sherki et al., 2001; Farooqui 
& Farooqui, 2009). ROS oxidise important cellular component such as lipids, protein 
and DNA to cause cellular damage (Ricciarelli et al., 2007) and eventually cell death 
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mainly by apoptosis (Gilgun-Sherki et al., 2001). Oxidative molecular damage to 
DNA and proteins increase exponentially with age (Calabrese et al., 2001) mainly due 
to a progressive decline in the ability of the human body to combat environmental 
stress and to successfully repair DNA fault (Sas et al., 2007). 
2.2.3: Excitotoxicity in neurodegeneration 
 Neurons are excitable cells designed to have sophisticated membrane ion 
channels and their excitatory neurotransmitter receptor systems are inherently 
sensitive to cation overload and oxidative damage caused by ROS (Raffray & Cohen, 
1997). Excitotoxicity is a process which involves over activation of excitatory 
neurotransmitter receptors accompanied by decreased inhibitory processes mediated 
by gamma amino butyric acid (GABA) and glycine (Gonsette, 2008) and finally leads 
to neuronal cell death. This is either by rapid necrosis or delayed apoptosis depending 
on the severity of the insult, extent of energy recovery (Kaul & Lipton, 2000) or 
glutamate exposure to its receptors. 
 
Figure 2.2: Direct and indirect toxicity hypothesis associated with CNS disorders.  
Diagram shows the interaction between the direct and indirect toxicity hypothesis in the 
etiology of various neurodegenerative disorders. Focusing on the common NMDA bridge 
between the two hypothesis which results in excitotoxic damage to brain. In direct toxicity, 
there is a overactivation of NMDA due to continuous stimulating response under pathological 
conditions whereas in indirect toxicity there is an impairment of mitochondrial function which 
results in the cascade of excitotoxic pathways leading to various neurodegenerative disorders 
(Mehta et al., 2013). 
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Excitotoxic neuronal death can be direct or through indirect pathways (figure 
2.2). Direct excitotoxicity is the result of excessive stimulation of NMDA receptors 
that was initially proposed as a causative factor in the pathogenesis of 
neurodegenerative disorders. In ‘indirect excitotoxic hypothesis’, depolarisation by 
bioenergetics deficit causes even the non-toxic levels of glutamate ultimately to 
become lethal (Mehta et al., 2013). 
 
Figure 2.3: Interaction of Ca
2+
 and mitochondria in ALS as a local disruptive feedback 
mechanism. Several research reports indicate an impairment of the mitochondrial respiratory 
chain in ALS (complex I – complex IV), which has multiple implications for Ca2+ regulation 
in motor neurons. First, impairment of complex VI presumably increase ROS production, 
which leads to reduced glutamate uptake in neighbouring glia cells, elevated glutamate levels 
in synaptic cleft and increased calcium influx through Ca
2+
-permeable glutamate receptor 
channels. Second, disturbed mitochondria affect cytosolic calcium regulation by a reduction 
of mitochondrial Ca
2+
 uptake/sequestration and an impaired function of Na/Ca exchanger in 
the inner mitochondrial membrane. Taken together, these disturbances might form a local 
feedback mechanism that contributes to motor neuron degeneration in ALS (Grosskreutz et 
al., 2010). 
Normally glutamate, the principal excitatory neurotransmitter in mammalian 
CNS, (Doble, 1999; Hogg et al., 2005; Barber et al., 2006; Betzen et al., 2009) and 
related compounds are stored within intracellular compartments with extracellular 
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glutamate retrieved via plasma membrane transporters. Other excitatory 
neurotransmitters include quinolinic, ibotenic, kainic, quisqualic and domoic acids. 
Astrocytes also take up glutamate from the extracellular spaces via excitatory amino 
acids (EAA) transporters and convert it to glutamine via ATP dependent mechanisms. 
In turn, neurons take up glutamine release by astrocytes from extracellular spaces and 
convert it back to glutamate via glutaminase (Gonsette, 2008). This ensures 
extracellular levels are precisely controlled, keeping it at physiological concentration. 
Figure 2.3 illustrates the processes involved in the release, uptake, and metabolism of 
glutamic acid and glutamine by glutamatergic nerve terminals and glial cells 
(astrocytes) at a central synapse (Doble, 1999). 
In cases of anoxia (Doble, 1999), CNS trauma, stroke, epilepsy and certain 
neurodegenerative diseases, increased concentrations of extracellular glutamate are 
caused either by excessive vesicular release (Stone & Addae, 2002), transporter 
reversal, disruption of cellular uptake, astrocyte dysfunction, or liberation of 
glutamate following necrotic cell lysis, which further results in the over-activation of 
local ionotropic glutamate receptors (iGluR) (Greenwood & Connolly, 2007). 
Astrocytes also serve as the major homeostatic regulator, buffers for excess 
neurotransmitters, neurophic factor secretors (Block & Hong, 2005), and as storage 
site for manganese in the brain but increased accumulation may alter release of 
glutamate and elicit excitotoxicity (Milatovic et al., 2009). They become activated in 
response to immunologic challenges or brain injuries to prevent neuronal death. 
However, activated astrocytes become hypertrophic, exhibit increased production of 
glial fibrillary acidic protein, and form glial scars, which hinder axonal regeneration 
(Block & Hong, 2005). Na
+
/K
+
 pump failure caused by cellular ATP depletion also 
has a depolarising effect on neurones resulting in excess release and accumulation of 
glutamate (figure 2.3; Le Feuvre et al., 2002).  
The iGluRs activated are NMDA, kainate and alpha-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA; Wollmuth & Sobolevsky, 2004; Mayer, 
2011). Although they share a common endogenous ligand, they show numerous 
pharmacological, biochemical and modulatory differences (Wollmuth & Sobolevsky, 
2004). The AMPA receptors are permeable to Na
+ 
and K
+
; and also permeable to Ca
2+
 
unless the receptor contains a GluR2 subunit that in most cases is absent (Aarts & 
Tymianski, 2003; Marambaud et al., 2009; Grosskreutz et al., 2010). The NMDA 
receptors are highly permeable to Ca
2+
 and Na
+
. Thus, over-activation of these 
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receptors results in excessive influx of Ca
2+
 and Na
+ 
leading to Ca
2+
 overload (delayed 
phase) and osmotic swelling (early phase) of the neuronal cellular bodies and dendrite 
spines respectively (Aarts & Tymianski, 2003). The osmotic component is potentially 
reversible if the stimulus is removed as the osmotic swelling will be prevented. Thus 
it is the calcium-dependent part of the excitotoxic cascade that appears to be essential 
for the initiators of excitotoxicity (Doble, 1999). The delayed Ca
2+
-dependent phase 
has been the target of pharmacological interventions aimed at protecting neurons 
against glutamate-induced excitotoxicity by preventing either Ca
2+
 influx or its 
intracellular release (Abdel-Hamid & Balmbridge, 1997). Voltage sensitive calcium 
channels are also activated to increase intracellular Ca
2+
 upon glutamate stimulation 
(Crews et al., 1998). However, Ca
2+
 overloading from this channel during KCl-
depolarisation is much less excitotoxic (Nicholls & Budd, 1998). Nicholls and Budd 
suggested that initial Ca
2+ 
entry (Ca
2+
 loading) in polarised cells may be more critical 
than the absolute amount of accumulated (Ca
2+
) in triggering excitotoxicity. Cell 
death does not depend on this initial Ca
2+ 
rise, but rather invariably follows a delayed 
massive accumulation of Ca
2+
, occurring a few hours after the toxic challenge and 
representing a no-return transition into the death process (Celsi et al., 2009). Although 
Ca
2+
 plays a key role in the pathology underlying neurodegeneration, it is not the sole 
mechanism mediating neuronal cell death (Choi et al., 1988; Grobler et al., 2006). 
  
 
Figure 2.4: Cartoon of possible points along the corticostriatal pathway where dysfunction 
may contribute to excitotoxicity. Excitotoxic neuronal death may result from a combination 
of: (1) increased glutamate release from cortical afferent; (2) reduced uptake of glutamate by 
glia; (3) hypersensitivity augmentation of mGluR signalling; (4) altered intracellular calcium 
homeostasis; and/or (5) mitochondrial dysfunction (Fan & Raymond, 2007). 
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Normally, the mitochondria possess the ability to sequester large quantities of 
intracellular Ca
2+
 within their matrices whenever local cytoplasmic free 
concentrations rise above the critical point, particularly in severe cellular dysfunction 
(Celsi et al., 2009; Nicholls & Budd, 1998; Greenwood & Connolly, 2007). However, 
massive Ca
2+ 
loading of the mitochondrial matrix activates the permeability transition 
pore (PTP) in the inner mitochondrial membrane (Greenwood & Connolly; 2007; 
Marambaud et al., 2009) thus exceeding the capacity of Ca
2+
 regulatory mechanism 
(Aarts & Tymianski, 2003). Activation of PTP and sodium ion influx leads to 
complete depolarization and collapse of mitochondrial membrane potential (ΔΨm) 
(figure 2.1) accompanied by ATP hydrolysis (Kaul & Lipton, 2000), generation of 
ROS, rupture of the outer mitochondrial membranes, and the release of the 
accumulated matrix Ca
2+
 (Greenwood & Connolly, 2007). ATP depletion (Nicholls & 
Budd, 1998), ROS, and excessive intracellular Ca
2+ 
accumulation activate the chain of 
events leading to channellopathy, calcium overload, mitochondriopathy, proteolytic 
enzyme production and activation of pathways leading to cell death (figure 2.4; 
Gonsette, 2008; Calabrese et al., 2001). Disturbance of Ca
2+
 homeostasis can also be 
caused by inflammation and Aβ-induced mitochondrial dysfunction, particularly 
Alzheimer disease, leading to apoptosis or necrosis (Witte et al., 2010). 
Krantic et al. (2005) reviewed the involvement of MPTP in excitotoxicity. It 
was indicated that MPP
+
 blocks complex I of the mitochondrial respiratory chain, 
consequently inhibiting oxidative phosphorylation and leading to decrease in 
intracellular ATP levels. These events are directly involved in neuronal 
depolarization, release of glutamate and over-stimulation of NMDA receptors 
(Krantic et al., 2005). Importantly, excessive Ca
2+
 influx also activates the stress-
related p38 mitogen-activated protein kinase (p38 MAPK)/myocyte enhancer factor 
2C (MEF2C transcription factor) pathway and c-Jun N-terminal kinase (JNK) 
pathways in cerebrocortical or hippocampal neurons. Activation of these pathways 
has been implicated in neuronal apoptosis (Kaul & Lipton, 2000).  
It has been suggested that in contrast to what is observed with NMDA receptor 
agonists, administration of AMPA/kainate receptor agonists into the CNS can lead to 
an apoptotic rather than a necrotic form of cell death in vivo. This would be 
compatible with the idea that AMPA/kainate receptor-mediated excitotoxicity 
involves sustained, low-level insult (Doble, 1999). Glutamate stimulation of NMDA 
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receptors also initiate endothelial barrier dysfunction, a phenomenon termed 
‘endothelial excitotoxicity’ (Betzen et al., 2009). 
 
Figure 2.5: Mechanisms of NO-mediated neurotoxicity. Exposure of astrocytes to cytokines 
leads to the induction of iNOS, generation of NO, and mitochondrial respiratory chain 
damage. Superoxide radicals generated by the respiratory chain further react with NO, 
forming ONOO
- 
and causing more mitochondrial damage. Despite this mitochondrial damage, 
astrocytic ATP levels are maintained by switching to glycolysis. Diffusion of NO into 
neighbouring neurons causes neuronal glutamate release, which then activates NMDA-type 
glutamate receptors, either on the same or neighbouring neurons. Activation of the neuronal 
NMDA receptor triggers Ca
2+
 influx and activation of nNOS. The subsequent generation of 
NO/ONOO
-
 initiates neuronal mitochondrial damage, lipid peroxidation, and ATP depletion. 
Since neurons are unable to increase glycolysis to maintain their energy demands, cell death 
may ultimately occur (Stewart & Heales, 2003). 
Nitric oxide (NO) is generated following activation of three isoforms of NO 
synthases (NOS); the endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). 
These isoforms differ from each other in terms of intracellular localization, activation 
properties and sensitivity to regulation by protein interactions and second messenger 
molecules. Neuronal NO synthase is constitutively expressed in neurons and 
astrocytes and associated more often with physiological actions of NO, while iNOS is 
induced by proinflammatory conditions in microglia, astrocytes and neurons, and 
mediates generation of NO in pathophysiological conditions (De Palma et al., 2008). 
Upregulation of iNOS can produce large amount of NO (Witte et al., 2010).  The role 
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of eNOS in the nervous system has been studied only to a limited extent (De Palma et 
al., 2008). 
NO can induce physiological response like vasodilatation, but massive influx 
of Ca
2+
, upon activation of excitotoxic stimulus, can over-activate neuronal nitric 
oxide synthase leading to excessive production of NO. The NO produced is capable of 
combining with free radicals generated from the mitochondria to form highly toxic 
peroxynitrite that contribute (by lipid peroxidation, protein nitration and DNA 
damages) to neuronal cell death (Chung & David, 2010). Exposure of neurons to NO 
can cause neuronal glutamate release which in turn stimulates NMDA receptors thus 
enhancing excitotoxicity. Glial-derived NO is also capable of eliciting neuronal 
glutamate release hence stimulating further formation of reactive nitrogen species to 
cause neuronal death (figure 2.5; Stewart & Heales, 2003). 
Activation of metabotropic glutamate receptors (mGluR), anchored to the 
NMDA Receptors via a chain of scaffold proteins i.e. receptors coupled to G protein 
(Rodriguez et al., 2000), can either modulate neurodegeneration or neuroprotection.  
mGlu 1a and 5 can stimulate intracellular Ca
2+
 release via hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2), a substance that ensure the 
formation of inositol-1,4,5-trisphosphate (InsP3), and activate the 
phosphatidylinositol-3-kinase (PI3K) pathway. This is known to support neuronal 
survival by inhibiting glycogen synthase kinase-3β and other mechanism, only if the 
C-terminus domain is intact. In conditions where elevated intracellular Ca
2+
 level 
cause a calpain-mediated cleavage of the C-terminus portion of the mGlu1a receptor, 
the PI3K pathway is prevented but leaves its ability to stimulate PtdIns-4, 5-P2 
hydrolysis intact (Pellegrini-Giampietro et al., 1999; Caraci et al., 2012). This may 
cause an imbalance in favour of the neurotoxic signal which results in neuronal death. 
In contrast to mGlu1 and mGlu5 agonists, mGlu1 and mGlu5 antagonists or negative 
allosteric modulators are consistently neuroprotective, by enhancing GABA release, 
independently of the nature of insult (Bordi & Ugolini, 1999; Nicoletti et al., 1999; 
Pellegrini-Giampietro et al., 1999; Caraci et al., 2012). mGlu2 and mGlu3 receptor 
activation have also shown neuroprotective activity. They reduce neuronal excitability 
by activating different K
+
 channel and negatively regulate glutamate release (Di 
Liberto et al., 2010; Caraci et al., 2012).  
Interestingly, glial-mGlu3 (mGlu3 in astrocytes) receptors are neuroprotective. 
They also regulate the production of neurotrophic factor, to stimulate neuronal 
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regeneration (Caraci et al., 2012). Neurotrophic factors play a vital role in the 
neuroprotection of specific neuronal population by suppressing the expression of 
‘suicide genes’ which, when activated are involved in the induction of the apoptotic 
processes (Connor & Dragunow, 1998). Other mGluRs which include: mGlu4, 
mGlu7, and mGlu8 are presynaptically localized and behave as autoreceptors 
inhibiting glutamate release. Metabotropic glutamate receptors involvement in 
excitotoxicity is still a ‘hot topic’ that warrant further investigation (Caraci et al., 
2012). 
Although both ionotropic and metabotropic glutamate receptors are involved 
in excitotoxicity, ionotropic glutamate receptors pose greater danger as its stimulation 
triggers neurodegeneration with little or no hope of neuronal survival. 
2.3: NMDA receptors 
2.3.1: Introduction 
 Ionotropic glutamate receptors mediate the fast response to the major 
excitatory neurotransmitter in human central nervous system and play an essential role 
in its development and function. Many neurological disorders such as epilepsy or 
chronic neurodegenerative conditions, as well as stroke, can be linked to iGluRs 
(Stawski et al., 2010; Jensen et al., 2011). Glutamate-induced excitotoxicty in aging 
or pathological conditions play a central role in acute and chronic neurodegenerative 
disorders and is a fundamental target in neuroprotective strategies (Gascon et al. 
2008). Although mGluR and iGluR are both stimulated in glutamate-induced 
excitotoxicity, iGluRs effects are more detrimental. This is due to the neuroprotective 
properties of mGluRs. Notwithstanding, they potentiate iGluR functions, 
downregulating K
+
 channel and upregulating non-selective cation channel, and inhibit 
GABA receptor activity to enhance neuronal excitability (Aarts & Tymianski, 2003). 
Among the iGluRs, NMDA receptor stimulation produces the major effect. NMDA 
receptors have several unique pharmacological and biophysical features, including the 
requirement for simultaneous binding of the co-agonist glycine and glutamate for 
activation (Monaghan et al., 2012), slow deactivation, voltage-dependent Mg
2+
 block, 
and high permeability to Ca
2+
, that distinguish them for other iGluRs (Chen & Roche, 
2007; Hedegaard et al., 2012).   
 Under most physiological conditions or at resting membrane potentials, 
NMDA receptors are blocked by magnesium ions, a voltage-dependent process, that 
prevent them from being activated by glutamic acid, but the blockage is relieved 
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either by AMPA- or kainate-mediated depolarisation, or pathological conditions. This 
contributes to excitotoxicity (Dobles, 1999; Stone & Addae, 2002). 
2.3.2:  Structure of iGlu receptor 
 The iGluR subunits contain three transmembrane domains (M1, M3 and M4) 
and a re-entrant membrane loop (M2) on the cytoplasmic side that lines the inner 
channel pores and defines the distinct ion selectivity of the ion channel. The large, 
extracellular amino-terminal domain of each subunit includes a necessary component 
of the glutamate recognition site (S1) and customises selective receptor modulation 
via several mechanisms including redox modulation of interdomain disulfide linkages 
or affinity to allosteric modulators such as extracellular protons, Zn
2+
 and polyamines. 
The M3-M4 loop includes a second required component of the glutamate recognition 
site (S2) and RNA splice variants that affect receptor desensitisation. The intracellular 
carboxyl terminus is involved in signal transduction, receptor anchoring and contains 
phosphorylation sites that modulate receptor activity (figure 2.6). Each subunit is a 
glycosylated, membrane-inserted polypeptide with an approximate length of 900 
amino acids (Bigge, 1999; Tichelaar et al., 2004; Mandolesi et al., 2009). 
 
 
Figure 2.6: Topology of a single NMDA receptor subunit. N is the extracellular N-terminal; 
M1, M3, and M4 the three transmembrane regions; M2 the reentrant P-loop; and C the 
intracellular C-terminal. M1–M4 are spread out for clarity; their relative positions are 
unknown. S1 and S2 form the ligand binding site. The external portion of M3, indicated by 
black, may be involved in channel gating. Four subunits are thought to comprise a functional 
NMDA receptors (Bigge, 1999; Qian & Johnson, 2002). 
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2.3.3:  Structure and functions of the NMDA receptor 
 NMDA receptors are grouped into three identified subunits that include: NR1 
subunit, four distinct NR2 subunits (A-D) (Hogg et al., 2005), and two NR3 subunits 
(A and B) (Cull-Candy et al., 1998; Aarts & Tymianski, 2003; Mayer, 2005; Losi et 
al., 2006; Chen & Roche, 2007; Li & Han, 2008; Monaghan et al., 2012). The NMDA 
receptor is structurally made up of a large extracellular amino-terminal domain (N 
terminus) that contributes to ligand binding, four membrane domains (three true 
transmembrane segments and a re-entrant pore loop (Chen & Roche, 2007) and an 
intracellular carboxyl-terminal regulatory domain (figure 2.11; O’Brien et al., 1998; 
Hogg et al., 2005). The N terminus binds to agonists, antagonists, and modulators 
such as Zinc, protons, polyamines, which can finally control the opening of the ion 
channel or modulate ion channel function and desensitization behaviour (Qiu et al, 
2011). The NR2 subunits of the NMDA receptors are much larger (> 1300 amino acid 
residues) because of an extended intracellular carboxyl terminus containing 
phosphorylation sites that regulate receptor function and level of activation. The NR1 
is obligatory for channel activity of NMDA receptors, whereas the NR2 subunit 
confers specificity of functions (Bigge, 1999). The pharmacology of the channel is 
mainly determined by the type of NR2 subunits and by alternative splicing of NR1 
subunits (Losi et al., 2006). NR2 subunits also confer distinct physiological and 
biochemical properties to the NMDA receptor complex. The various NR2-containing 
receptors differ in their single channel conductance, open probability, the ability to 
desensitize, decay rate, sensitivity to L-glutamate and glycine, and the ability to bind 
to various intracellular signalling proteins (Monaghan et al., 2012).  
 The binding sites for glycine and glutamate are subunit NR1 and NR2 
respectively (Qian & Johnson, 2002; Chen & Roche, 2007; Hedegaard et al., 2012). 
However, glycine can act on glycine binding sites at synaptic NR2A and NR2B 
containing NMDA receptors to enhance NMDA receptor functions (Li & Han, 2008).   
 Of the previously mentioned iGluR families, activated by glutamate, the 
NMDA receptor family has received special attention. This is due to it distinct role in 
regulation of synaptic plasticity- long-term potentiation, long-term depression, and 
experience-dependent synaptic refinement (Costa et al., 2012). In addition, its role is 
critical in neurological and psychiatric disorders (Monaghan et al., 2012). 
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2.3.4: NMDA receptor binding sites 
The overall fold of the ligand-binding domains of iGluR families (AMPA, 
kainite and NMDA receptors) are nearly identical. They possess key amino acid side 
chains that interact with ligand α-amino and α-carboxyl groups. What differs are the 
amino acids that interact with the glutamate γ-carboxyl groups or, in the case of NR1 
subunits, prevent the binding of glutamate. In the agonist-bound complex of all 
iGluRs, the ligand is buried in the interior of the protein but the volume of the ligand-
binding cavity varies substantially (Mayer, 2005). The S1 and S2 adjacent to M1 and 
the M3-M4 loop respectively form a bi-lobed glutamate binding pocket that is in 
dynamic equilibrium between open and closed gate. Short segments linking the 
recognition site to the transmembrane domains play a central role in the gating of 
NMDA receptor channel and glutamate binding induces conformational changes that 
create mechanical tension in M1 that activate the channel (figure 2.6). 
 Glutamate binds to NR2 subunits and glycine binds to a homologous site on 
NR1 and NR3 subunits, to cause the opening of the receptor’s Na+/K+/Ca2+- 
permeable ion channel. It is the influx of Ca
2+
 ions through this channel that initiates 
many of the actions of the NMDA receptors (Monaghan et al., 2012). 
2.3.5: NMDA receptor inhibition 
 NMDA receptor antagonism may have therapeutic application. This has led to 
the study and development of several NMDA antagonists with diverse mechanisms of 
action with a hope to treat disorders such as stroke, hypoxic injury, pain and 
neurodegeneration (Monaghan et al., 2012). Despite high expectations, the results 
from clinical studies of NMDA receptor antagonists have been largely disappointing 
(Costa et al., 2012). Antagonists that functionally inhibit NMDA receptors via either 
the binding site on the regulatory N-terminal domain (Monaghan et al., 2012), PCP 
site located inside the channel (open channel block) (Geldenhuys et al., 2007), the 
primary transmitter binding site (competitive) or the strychnine-insensitive glycine 
site (glycineB) (Parsons et al., 1999; Kiss et al., 2005; Monaghan et al., 2012) show 
inadequate selectivity among different subtypes of NMDA receptors and have been 
plagued by unacceptable side effects such as psychotomimetic effects and impaired 
motor function (Kiss et al., 2005). Compounds like PCP, ketamine and MK-801 
(figure 2.7) produce these undesirable side effects owing to high affinity for NMDA 
receptors (Doble, 1999; Monaghan et al., 2012). These compounds are uncompetitive 
antagonists of NMDA receptors and are highly potent (Doble, 1999). MK-801 for 
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example, slows the blocking rate and allows significant Ca
2+
 influx such that very 
high concentrations of MK-801 are required to completely block NMDA triggered 
Ca
2+
 responses, producing long-lasting, maximal blockade of the channel (Black et 
al., 1996). As a result, only few compounds targeting these receptors have been 
converted from pre-clinically active compounds into drugs for human use.  
NH
CH3
N
Phencyclidine (PCP) Ketamine
Dizolcipine (MK-801)
NH
CH3
O
Cl
 
Figure 2.7: Chemical structures of phencyclidine, ketamine and dizolcipine.  
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Dextromethorphan Remacemide
Aptiganel Amantadine  
Figure 2.8: Chemical structures of memantine, dextromethorphan, remacemide, aptiganel and 
amantadine. 
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Figure 2.9: Scheme of the hypothesis explaining how the fast unblocking kinetics of 
memantine allows this strongly voltage-dependent compound to differentiate between the 
physiological and pathological activation of NMDA receptors (Parsons et al.; 1999). 
Low-affinity un-competitive antagonists and allosteric modulators of NMDA 
receptors have demonstrated improved safety profiles compared to competitive 
antagonists, which have failed in clinical trials due to their narrow therapeutic window 
(Hedegaard et al., 2012). These clinically-tolerated NMDA receptor channel blockers 
include: memantine, dextromethorphan, remacemide, aptiganel and amantadine 
(figure 2.8; Monaghan et al., 2012; Doble, 1999). The reduce toxicity or safety profile 
is probably due to faster rates of unblocking (memantine; figure 2.9) and equilibrium 
block (Black et al., 1996). These compounds produce shorter-acting channel block 
with lower potency (Doble, 1999). 
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2.4:  Neuronal voltage-gated calcium channels 
2.4.1: Introduction 
 In the central nervous system, calcium influx through VGCC mediates a range 
of cytoplasmic processes, including vesicular release of neurotransmitters, 
intracellular signalling pathways, gene expression, synaptic plasticity, and regulation 
of neuronal excitability (Snutch et al., 2001; McDonough, 2007; Christel & Lee, 
2012; Morton et al., 2013). The electric potential across cellular membranes is 
controlled by a gradient of ions produced by membrane pumps, buffering molecules 
and the activity of the ion channels themselves, either in response to the electrical 
gradient (voltage sensing ion channels) or inter- and intra-cellular chemical 
messengers (ligand-gated ion channels). Voltage-gated calcium channels respond to 
neuronal membrane depolarisation by opening and allowing conductance of the 
calcium ions down the gradient of voltage across the membrane to activate various 
physiological functions (Hurley & Dexter, 2012). In addition to their normal 
physiological function, Ca
2+
 channels are also implicated in a number of neurological 
disorders such as neuropathic pain, epilepsy, Parkinson’s disease, Alzheimer’s disease 
and other neurodegenerative disorders (Snutch et al., 2001; Solntseva et al., 2007; 
Hurley & Dexter, 2012). Under these pathological conditions, there is elevation of 
intracellular calcium due to slower or longer-lasting increase of Ca
2+
 entry via 
VGCCs that results in calcium overload. The overload disrupts Ca
2+
 signalling, alters 
neuronal excitability and neurotransmitter release, and can cause cell death (Bailey et 
al., 2013). This contributes to neuronal degeneration in many neurodegenerative 
disorders. Therefore, the blockage of VGCC is a desirable pharmaceutical property 
for neurodegenerative disorder therapy (Solntseva et al., 2007). 
2.4.2: Structure of VGCC 
 The neuronal VGCC are subdivided into four different types that include the 
L, N, P/Q and R (Triggle, 1999; Hurley & Dexter, 2012). These are high-voltage-
activated channels that can be distinguished by their unique pharmacological, kinetic, 
and voltage-dependent gating characteristics (Triggle, 1999; Snutch, 2009). They are 
multi-subunit complexes (Christel & Lee, 2012) that comprised of a pore-forming α1 
subunit and auxiliary β, α2, γ, and δ subunits (Fontaine et al., 1997; Arikkath & 
Campbell, 2003; Wong et al., 2006; Conte Camerino et al., 2007; Morton et al., 
2013). Each subunit consists of amino and carboxyl termini (Buraei & Yang, 2013). 
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The entire complex appears to be roughly cylindrical, with dimensions of 
approximately 9 nm wide by 20 nm high (figure 2.10; Snutch, 2009). 
 
Figure 2.10: Subunit composition of VGCC complex (Snutch, 2009).  
 The α1 subunit complexed with one or more auxiliary β determines the main 
gating and permeation properties (McDonough, 2007), whereas the other subunits 
modulate various properties of the α1 subunits (Snutch et al., 2001; Snutch, 2009). 
The pore-forming α1 subunit is a single peptide chain consisting of a fourfold internal 
repeat; each repeat has six membrane-spanning domains (1-6) with substantial α-
helical character. Primary sequence of the four internal repeats is homologous but 
non-identical (McDonough, 2007). The intracellular β subunit has α-helices but no 
transmembrane segments, while the γ subunit is a glycoprotein with four 
transmembrane segments. The cloned α2 subunit has many glycosylation sites and 
several hydrophobic sequences, but biosynthesis studies indicate that it is an 
extracellular, extrinsic membrane protein, attached to the membrane through disulfide 
linkage to the δ subunit. The δ subunit is encoded by the tertiary end of the coding 
sequence of the same gene as the α2 subunit, and the mature forms of these two 
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subunits are produced by posttranslational proteolytic processing and disulfide linkage 
(figure 2.11; Catterall, 2010). 
 
Figure 2.11: Subunit structure of Ca
2+ 
channels. 
The subunit composition and structure of Ca
2+
 channels purified from skeletal muscle are 
illustrated. The model is update description of the subunit structure of skeletal muscle Ca
2+
 
channels. This model also fits most biochemical and molecular biological results for neuronal 
Ca
2+
 channels (Catterall, 2011). 
2.4.3: Structure and functions of VGCC 
 VGCC expression is widespread throughout the brain, but each subtype has a 
unique distribution. The neuronal VGCC L-subtypes are found on cell bodies, 
proximal dendrites of projection neurons and some interneurons in cerebral cortex, 
hippocampus, cerebellum and spinal cord and they are responsible primarily for 
excitation-contraction coupling, synaptic plasticity and neurotransmitter release. The 
N, P/Q and R subtype are predominantly associated with presynaptic terminal, and 
they play a role in regulating neurotransmitter release. They are also present on the 
cell body and dendrites of neurons, where they regulate depolarisation (Hurley & 
Dexter, 2012). 
The α1 subunit contains the essential elements for ion permeation, gating, and 
pharmacology (He et al., 2007). The α1 subunit defines the calcium channel subtype 
and contains all the molecular machinery to produce a functional channel, such as p-
loops that permit ion permeation and selectivity, voltage sensors that allow the 
channel to respond to membrane depolarisation, and intrinsic inactivation machinery 
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(Jarvis & Zamponi, 2007). It is a large hydrophobic protein with 24 transmembrane 
regions distributed over four domains and forms the voltage sensor and the pore of the 
channel to allow Ca
2+
 influx into the cell in a voltage-dependent manner (figure 2.11; 
Arikkath et al., 2002). 
The α2 and δ subunits, linked by disulphide bridges, form a single functional 
subunit (α2δ) that enhances the activity of α1. A topological analysis support a model 
for the protein in which α2 is entirely extracellular and δ has a single transmembrane 
region with a very short intracellular portion, which serves to anchor the protein in the 
plasma membrane. Although δ is the portion of the protein that is anchored in the 
membrane, it is α2 that interacts with the α1 subunit (figure 2.10). Of the four 
genetically distinct α2δ subunits (α2δ-1 - α2δ-4) described in the literature, only three 
subunits (α2δ-1 - α2δ-3) are expressed in the brain (Arikkath & Campbell, 2003; 
Davies et al., 2007). The co-expression of α2δ-1 allows an enhancement in the 
membrane trafficking of α1, associated with an increase in the number of ligand 
binding sites. This subunit also causes an increase in current amplitude, faster 
activation and inactivation kinetics and a hyperpolarising shift in the voltage 
dependence of activation. The α2δ-2 subunit only appears to increase the current 
amplitude. The co-expression of α2δ-3 subunit with β subunit causes increase in 
current density, voltage dependent activation and steady state inactivation (Arikkath 
& Campbell, 2003). 
The β subunits are cytosolic proteins that switch its localisation from cytosolic 
to membrane-bound in the presence of α1 subunits. Without the co-expression, α1 
subunits show little and no surface expression and produce very small or no currents. 
Besides enhancing channel surface expression, they regulate channel gating and 
enhance channel activation and inactivation. All β subunits facilitates channel opening 
by shifting the voltage dependence of channel activation by ~ 10-15 mV to more 
hyperpolarised voltages. This is reflected as an increase in the open probability at the 
single channel level, with β2a producing the most dramatic increase in channel open 
probability. They also often speed channel activation. Calcium channel inactivation 
occurs in a voltage- and Ca
2+
 -dependent manner (VDI and CDI, respectively). This 
process is modulated by β subunits in three ways: (1) they shift the voltage 
dependence of inactivation to more hyperpolarised voltage ~ 10-20 mV, which 
enhances VDI and CDI. (2) Except for β2a, they promote calcium channels’ (N, P/Q 
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and R) ‘closed state’ inactivation. (3) They generally accelerate inactivation kinetics, 
but β2a and β2e, decelerate inactivation kinetics (Buraei &Yang, 2013).  
The expression of γ subunits show wide tissue distribution, but the γ1 subunit 
expression is restricted to skeletal muscle. The γ subunits in the brain produce effects 
that include inhibitory effect, activation/inactivation kinetics, trafficking of AMPA 
receptor and reduction of recurrent amplitude (Arikkath & Campbell, 2003). 
2.4.4: Neuronal VGCC inhibition 
Activation of VGCC mediates calcium-dependent processes that play 
important roles in regulating various neuronal physiological functions (Takahashi & 
Ogura, 1983). However, disruption in calcium signalling as a result of pathological 
elevations of intracellular calcium concentration can occur and lead to the 
inappropriate activation of normally dormant (or low level) calcium-dependent 
processes, which in turn, result in metabolic disturbances and eventually 
neurodegeneration (Grobler et al, 2006). The ideal drug targets should focus on 
reducing intracellular calcium ion from overload to normal physiological level. This 
prevents neuronal cell death caused by excitotoxicity. VGCC are such target, since 
they not only mediate calcium influx in response to membrane depolarisation, but are 
also crucial in the release of neurotransmitters like glutamate, an excitatory 
neurotransmitter (Varming et al., 1996). Thus, agents that modulate voltage-gated 
calcium channels are of interest in the treatment of conditions associated with 
neurodegeneration. Such agents are mainly neuronal VGCC blockers that exhibit 
neuroprotective properties (Scott et al., 2012). 2-amino-1-(2,5-dimethoxyphenyl)-5-
Trifluoromethyl benzimidazole (NS-649) is a non-selective  neuronal VGCC blocker 
that protects cultured neurons from degeneration caused by energy depletion. VGCC 
blockers such as ziconotide (Wang et al., 2000; Snutch et al., 2001), A-686085, A-
1048400, NP118809, NP078585 (Zamponi et al., 2009), TROX-1, Z123212 
(Hildebrand et al., 2011), and TTA-P2 (figure 2.12; Choe et al., 2011) have been 
described to block neuronal VGCC without significant cardiovascular or CNS side-
effects. These compounds have shown to effectively produce antinociceptive effect 
(Scott et al., 2012). Although these antinociceptive agents have not been reported in 
the literature as neuroprotective agents, mechanism of action suggests the possibility 
of potential neuroprotective activities. Dihydropyridine and polycyclic cage 
compounds such as nimodipine and NGP1-01 have shown to reduce excitotoxicity by 
blocking VGCC. This offers protection to neuronal cells susceptible to calcium 
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overload. Amlodipine and azelnidipine, dihydropyridine derivatives, are VGCC 
blockers that prevent intracellular calcium accumulation and protect neuronal cells 
(Lukic-Panin et al., 2007). This strongly suggests that drugs acting as antagonists, 
selective or non-selective, on voltage-gated calcium channels may function as 
neuroprotective agents in disorders associated with excitotoxicity (Lockman et al., 
2012). 
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Figure 2.12: Chemical structures of voltage calcium channel blockers. 
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2.5: Polycyclic derivatives 
2.5.1: Introduction 
The polycyclic cage structure has been of interest to chemists for more than 50 
years, but only recently has the medicinal possibilities of these cage compounds been 
explored (Geldenhuys et al., 2009). They are an interesting and highly promising 
group of compounds that are receiving intense scrutiny as potential chemical scaffolds 
for the development of new drugs (Geldenhuys et al., 2007). The uncompetitive 
NMDA receptor blockers, memantine and amantadine, are polycyclic cage-like 
compounds with established neuroprotective properties. Although the biological 
activities of these compounds were found serendipitously, it has led to considerable 
interest in the development and studies of several cage-like rigid polycyclic 
molecules. The structural perculiarities of these cage-like molecules may not only 
enable them to interact with biological receptors and/or trap smaller chemical species 
in their interior, but also minimise metabolic degradation (Ito et al., 2007). 
O
NH
NGP1-01
 
Figure 2.13: Chemical structure of NGP1-01. 
Pentacycloundecane derivatives such as pentacycloundecylamine (NGP1-01; 
figure 2.13), a polycyclic amine, is one of the cage-like rigid polycylic molecules that 
exhibit L-type voltage-gated calcium channel (VGCC) block (Geldenhuys et al., 
2004; Joubert et al., 2011) and potent uncompetitive NMDA receptor channel 
inhibition (Hao et al., 2008). It is also referred to as a multifunctional ion-channel 
blocker (Mdzinarishvili et al., 2005; Van Der Schyf & Geldenhuys, 2009). These dual 
inhibitions attenuate the calcium entry pathway, thus preventing neuronal damage 
(Mdzinarishvili et al., 2005; Youdim, 2010). In an experiment performed by Van Der 
Schyf and Geldenhuys on a mouse brain, it was proven that NGP1-01 is more potent 
when compared with memantine. In addition to its neuroprotection properties, it can 
cause PQ-interval prolongation and increased antrioventricular conduction in the 
heart, therefore, may have use in treating heart arrhythmias (Van Der Schyf & 
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Geldenhuys, 2009). This compound also exhibits favourable distribution to the brain 
and therefore penetrates the blood-brain barrier readily (Prins et al., 2009). 
Biological activity are attributed to the pentacycloundecylamines, thus 
suggesting possible neuroprotective abilities through modulation of voltage activated 
sodium, potassium and Ca
2+ 
channels, as well as interaction with NMDA receptor 
operated channels. Studies evaluating the biological activity of these compounds 
indicate actions that include amongst others, neuroprotective activity, selectivity, and 
high affinity for the sigma receptor binding site (Grobler et al., 2006). 
Amine-triquinane derivatives, the product of thermal ring-opening of the 
pentacycloundecane cage skeleton and especially the benzylamine derivatives thereof 
has been suggested to interact with both the voltage-gated calcium channels and the 
NMDA receptor. This suggestion was based on their ability to completely suppress 
the action potential in guinea pig papillary muscle, and displace [
3
H]-MK-801 with an 
IC50 value of 1.9 µM when a series of amine-triquinane derivatives were screened 
against [
3
H]-MK-801 binding in murine synaptoneurosomes (Van Der Schyf & 
Geldenhuys, 2009). 
2.5.2: Structure-activity relationship of polycyclic derivatives 
The basic pharmacophoric requirement for NMDA receptor antagonists (PCP, 
MK-801 and polyamines) includes: a hydrophobic moiety which is the lipophilic area, 
an aromatic ring apparently required for high affinity to the receptor, and a basic 
nitrogen atom (protonated amine) that forms a hydrogen bond with the receptor 
(Leeson et al., 1990; Kroemer et al., 1998). Pentacycloundecylamines such as NGP1-
01 possesses all of these characteristics. The structure-activity relationships for 
pentacycloundecylamine appear to be determined primarily by geometric factors or 
steric constraints, with a small influence of electronic effects (Geldenhuys et al., 
2007; Van Der Schyf & Geldenhuys, 2009).  
Geldenhuys et al. (2007) pointed out in their study that the polycyclic cage amine 
seems to be the most important pharmacophoric element contained within the 
pentacycloundecane-amine structure required to interact with the NMDA receptor. 
The phenyl ring adds to the NMDA receptor interaction and thus increased 
antagonism. Substitution on the phenyl ring lowers its potency. It could be that the 
moiety is too bulky for the proposed ‘phenyl pocket’ with steric hindrance causing 
attenuated affinity and therefore reduced NMDA antagonism. However, this proposed 
steric interaction seems to be more tolerant toward substitution on the meta position 
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than the para position. The number of atoms between the amino and phenyl rings 
appears to play an important role in its activity. An increase in chain length from 
methyl to ethyl reduces NMDA receptor inhibition (Geldenhuys et al., 2007) probably 
due to increased steric and electronic interaction. However, an increase in chain 
length increase calcium channel (L-type) inhibition probably due to a deeper 
immersion into the calcium channel that might result in a stronger interaction with the 
putative binding site (Joubert et al., 2011). Electron donating methoxy moieties 
increase activity while electron withdrawing nitro moieties reduces the calcium 
channel inhibition (Geldenhuys et al., 2004). The donation of electrons makes the 
phenyl ring more lipophilic and would increase affinity for an aromatic π-π or 
hydrophobic interaction. Increase in cage size diminishes activity but an improvement 
may occur if there is increase in hydrophobicity (Geldenhuys et al., 2007). 
2.5.3: Pentacycloundecylamine-NMDA receptor interaction 
Interestingly, the binding of pentacycloundecylamines, such as NGP1-01, to 
the NMDA receptor is not to the PCP binding site. It was suggested that the phenyl 
ring undergoes a π-π type aromatic interaction with an aromatic amino acid located at 
the entrance of the NMDA receptor channel. Such an interaction would allow the 
molecules to be ‘anchored’ in such a way that the cage can descend into the channel 
lumen to a depth allowed by the ‘spacer’ between the nitrogen and the phenyl ring 
(Geldenhuys et al., 2007; Joubert et al., 2011). 
2.5.4: Tricycloundecane derivatives 
Tricyclo[6.2.1.0
2,7
]-undeca-4,9-dien-3,6-dione is an intermediate compound 
formed during the synthesis of pentacycloundecane (Scheme 1.1). Although this 
structure and its derivatives have been extensively synthesised, its use in medicinal 
chemistry has not been explored in depth (Ito et al., 2007). In this study, its 
derivatives with expected similar structure-activity relationships and NMDA receptor 
interaction as the pentacycloundecylamine, will be synthesized and evaluated for 
NMDA receptor and Ca
2+
 channel inhibition. 
2.6: Conclusion 
Neurodegenerative disorders are increasingly leading to morbidity and 
mortality in our society. The treatment of these disorders possesses perplexing 
challenges (Geldenhuys et al., 2011) that not only lie in difficult diagnoses, but also in 
design and development of drugs which may halt the degeneration process (Emard et 
al., 1995). Pathways to neurodegeneration are numerous and include amidst other; 
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extensive cascades of enzymatic events, cerebrovascular accidents, mutation in certain 
genes and excitotoxicity. Understanding these pathways has resulted in development 
of various compounds with potential neuroprotective activities. Although differences 
exist among these disorders, excitotoxicity is a common mechanism to all. Having 
highlighted the role of excitotoxicity, halting or reducing the degenerative process 
through blocking excitotoxicity would be a major breakthrough in the treatment of 
these disorders. Although numerous compounds have been developed, they have yet 
to reach clinical trials owing to their low safety profile. The vast majority of approved 
drugs for neurodegenerative disorders only offer symptomatic relieve to increase life 
expectancy of affected individual. 
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CHAPTER THREE 
Synthesis 
3.1: General 
The synthesis of the proposed series of compounds evaluated for NMDA 
receptor and calcium channel inhibition involved several experimental procedures and 
methods. Cycloaddition reaction between p-benzoquinone and monomerised 
dicyclopentadiene yielded tricycloundeca-4,9-diene-3,6-dione (1) which was used as 
the lead structure for all further synthesis (2-10). This compound (1) was further 
derivatised to yield a comprehensive series of compounds (1-10; Scheme 3.1). The 
compounds were synthesised to evaluate the effect of the open cage (1, 2, 3, 5, 6, 7, 8) 
moiety, rearranged cage (4, 9, 10) moiety, C=C (1 vs 2) and C=O (2 vs 3 and 9 vs 10) 
bond reductions, and tertiary (5, 7) and secondary (6, 8, 9, 10) amines on biological 
activity.
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Scheme 3.1: Synthetic route of tricycloundecane derivatives (1-10) and their respective 
yields. 
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3.2: Standard experimental procedures 
3.2.1: Reagents and chemicals 
Unless underwise specified, reagents used in the synthesis were obtained from 
Merck (St Louis, MO, USA) and Sigma-Aldrich
®
 (UK) and used without further 
purification. Solvents used for reactions and chromatography were purchased from 
various commercial sources and dried using standard methods. 
3.2.2: Instrumentation 
Infrared (IR) absorption spectrophotometer: Infrared spectra were obtained on a 
Perkin Elmer Spectrum 400 spectrometer, fitted with a diamond attenuated total 
reflectance (ATR) attachment. 
Mass spectrometry (MS): Mass spectra were obtained on waters API Q-Tof UItima 
mass spectrometer at 70 eV and 100 ºC. All HR-ESI samples were introduced by a 
heated probe and perfluorokerosene was used as a reference standard. 
Melting point (MP) determination: Melting points were determined using a Stuart 
SMP-300 melting point apparatus and capillary tubes. The melting points are 
uncorrected. 
Nuclear magnetic resonance (NMR) spectroscopy: 
1
H and 
13
C spectra were 
obtained at 200 MHz and 50 MHz respectively on a Varian Gemini 200 NMR 
spectrometer. Tetramethylsilane (TMS) was used as internal standard, with deuterated 
chloroform (CDCl3) as solvent. All chemical shifts are reported in parts per million 
using the internal standard (δ = 0) and the CDCl3 peaks as reference. The following 
abbreviations are used to indicate the multiplicity of respective signals: s-singlet; bs-
broad singlet; d-doublet; dd-doublet of doublets; t-triplet; and m-multiplet. 
Microwave synthesis system: Microwave synthesis was performed using a CEM 
Discover
TM
 focused closed vessel microwave synthesis system. 
3.2.3: Chromatographic techniques 
The mobile phases used for thin layer chromatography (TLC) and column 
chromatography were prepared on a volume-to-volume (v/v) basis using the prism 
model described by Nyiredy et al. (1985). 
Thin layer chromatography (TLC): The progress of all chemical reactions was 
monitored using thin layer chromatographic methods which also aided the isolation 
processes. Visualisation of thin layer chromatography was achieved using UV light at 
254 nm and 366 nm, iodine vapour and nihydrin (1.5%). 
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Column chromatography: Separation and purification of mixtures were performed 
using a standard glass column that is 50 cm in length with an inner diameter of 2.5 
cm. The stationery phase used was mesh 70-230 (63-200 µm) silica gel with mobile 
phases as indicated in section 3.3 for each compound. 
3.3: Synthetic procedures 
3.3.1: Tricyclo[6.2.1.0
2,7
]undeca-4,9-diene-3,6-dione (1) 
3
4
2
5
7
6
89
110
O
O
11
 
Synthetic method: To a solution of p-benzoquinone (10.0 g, 92.5 mmol) in 
100 ml benzene, a mixture of 100 ml hexane:ethyl acetate (5:1) was added and cooled 
to 0 
o
C. Monomerised cyclopentadiene (12.24 g, 185.2 mmol), in stoichiometric 
quantities, was slowly added to the resulting mixture and stirred for 4 hours. The 
solvents were removed in vacuo rendering the crude product as yellow crystals which 
was further purified by recrystallisation using hexane as the solvent to form 
compound 1 as pure yellow crystals (yield: 14.0 g, 86%). 
PHYSICAL DATA: 
C11H10O2; MW: 174.2 g/mol; Mp.: 69-73 
o
C, Literature: 71-75 ºC (Ito et al, 2007); 
IR (ATR; cm
-1
): 2987, 1660, 1604, 1281, 1055, 726 cm
-1
; 
13
C-NMR (50 MHz, 
CDCl3) δ (ppm): 199.4 (C-3/6), 142.0 (C-4/5), 135.2 (C-9/10), 49.5 (C-2/7), 48.7 (C-
11), 48.3 (C-1/8); 
1
H-NMR (200 MHz, CDCl3) δ (ppm): 6.38 (d, J = 1.8 Hz, 2H, H-
4/5), 5.86 (t, J = 3.6/1.8 Hz, 2H, H-9/10), 3.33-3.36 (m, 2H, H-1/8), 2.98-3.15 (m, 2H, 
H-2/7), 1.32-1.36 (AB-q, 2H, J = 8.8/5.2/1.8 Hz, H-11). 
STRUCTURE ELUCIDATION: 
In the infrared spectrum, the C=O bond was present as a sharp peak at 1660 cm
-1
 
while the C=C vibration was present at 1604 cm
-1
. In the 
1
H NMR spectrum, the 
doublet and triplet signals found downfield was assigned to H-4/5 (6.38 ppm) and H-
9/10 (5.86 ppm) respectively and the AB-quartet of the bridge at C-11 (1.32-1.36 
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ppm) was identified to confirm the structure of 1. The AB-quartet system has 
coupling constants of 1.8, 5.2 and 8.8 Hz. The 
13
C NMR spectrum presented 
resonance of the C=O at 199.4 ppm and C=C at 135.2-142.0 ppm and were detected 
downfield while the saturated and unsaturated carbons were identified upfield (48.3-
49.5 ppm). The physical data conformed to the literature and confirmed the formation 
of an endo adduct (Ito et al., 2007; Salles et al., 2012). 
3.3.2: Tricyclo[6.2.1.0
2,7
]undec-9-ene-3,6-dione (2) 
3
4
2
5
7
6
89
110
O
O
11
 
Synthetic method: Powdered zinc (6.00 g, 91.7 mmol) was added to a solution 
of compound 1 (4.0 g, 23.0 mmol) in 100 ml of glacial acetic acid. The resulting 
mixture was sonicated for 2 hours. After 2 hours, the mixture was filtered and the 
residue washed with CH2Cl2 (10 ml). The combined filtrates were added to brine (50 
ml) and shaken vigorously.  The layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 50 ml). The combined organic layers were washed with 
water (50 ml), a saturated aqueous NaHCO3 solution (100 ml) and again with water 
(50 ml). The organic layer was dried using anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The yellow oil formed was purified by silica gel 
column chromatography using hexane:ethyl acetate (3:1) as the eluent rendering the 
pure product as a yellow oil (yield: 3.02 g, 50.3%). 
PHYSICAL DATA: 
C11H12O2; MW: 176.2 g/mol; IR (ATR; cm
-1
): 2973, 1660, 1254, 1155, 1055, 725 
cm
-1
; 
13
C-NMR (50 MHz, CDCl3) δ (ppm): 209.6 (C-3/6), 136.6 (C-9/10), 51.8 (C-
2/7), 48.7 (C-11), 47.4 (C-1/8), 37.9 (C-4/5); 
1
H-NMR (200 MHz, CDCl3) δ (ppm): 
6.15 (t, J = 3.4/1.6 Hz, 2H, H-9/10), 3.43 (t, J = 3.2/1.4 Hz, 2H, H-1/8), 3.19 (m, 2H, 
H-2/7), 2.19-2.70 (m, 4H, H-4/5), 1.43-1.48 (AB-q, J = 10.8/6.8/2 Hz, 2H, H-11).  
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STRUCTURE ELUCIDATION: 
The spectra of compound 2 is similar to compound 1 except for the selective 
reduction of C=C bond at C-4/5. Upfield shifts were identified in both the 
1
H and 
13
C 
NMR spectra. In the IR spectrum, the signal at 1604 cm
-1
 assigned to C=C, which was 
present in compound 1, was absent in the spectra of compound 2, confirming the 
reduction of C=C at C-4/5. In the 
1
H NMR spectrum, the multiplet assigned to H-4/5 
was present at 2.19-2.70 ppm, the triplet asigned to H-9/10 was identified downfield 
(6.15 ppm), and the AB-quartet system of the bridge was identified at 1.43-1.48 ppm. 
In the 
13
C NMR spectrum, the spectrum was similar to compound 1 except for the 
13
C 
for C-4/5 which had shifted more upfield (37.9 ppm). The C=O and C=C peaks were 
identified at 209.6 ppm and 136.6 ppm, respectively. The physical data conformed to 
the literature (Ito et al., 2007; Salles et al., 2012). 
3.3.3: 6-hydroxytricyclo[6.2.1.0
2,7
]undec-9-en-3-one (3) 
3
4
2
5
7
6
89
110
OH
O
11
 
Synthetic method: A solution of compound 2 (0.61 g, 3.5 mmol) in a mixture 
of MeOH (12 ml) and H2O (2 ml) was cooled to 0 °C using an external ice-water bath. 
NaBH4 (0.045 g, 4.5 mmol) was added to the cooled mixture and allowed to warm to 
room temperature for 1 hour and then stirred continuously at room temperature for 2 
hours. Glacial acetic acid (0.1 ml) was added, followed by the addition of ice-water 
(10 ml). The resulting mixture was extracted with CH2Cl2 (2 x 30 ml). The combined 
organic layers were washed with water (30 ml), dried over anhydrous MgSO4, and 
filtered. The filtrate was concentrated under reduced pressure to afford the crude 
product as a yellow oil. The product was purified via silica gel column 
chromatography using hexane:ethyl acetate (3:2) as the eluent, yielding the desired 
compound as pale yellow oil (yield: 0.50 g, 82.7%) 
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PHYSICAL DATA: 
C11H14O2; MW: 178.2 g/mol; IR (ATR; cm
-1
): 3404, 2937, 1686, 1331, 1033, 739 
cm
-1
; 
13
C-NMR (50 MHz, CDCl3) δ (ppm): 212.9 (C-3), 137.4 (C-10), 134.6 (C-9), 
67.7 (C-6), 51.5 (C-2), 50.1 (C-11), 46.2 (C-1), 45.5 (C-7), 45.2 (C-8), 35.6 (C-4), 
28.0 (C-5).
 1
H-NMR (200 MHz, CDCl3) δ (ppm): 5.01 (d, J = 1.2 Hz, H-9), 4.13 (t, J 
= 7.0/3.4Hz, 1H, H-10), 3.11 (m, 1H, H-6), 2.89 (s, 1H, H-O), 2.62-2.76 (m, 2H, H-
1/8), 1.99-2.19 (m, 2H, H-2/7), 1.58-1.71 (m, 4H, H-4/5), 1.11-1.29 (AB-q, J = 
35.8/19/8.4/1.8 Hz, 2H, H-11).  
STRUCTURE ELUCIDATION: 
In confirming the structure of compound 3, the hydroxyl group attached to C-6 was 
identified despite the distinct spectral similarities with compound 2. The IR spectrum 
showed a broad peak present at 3404 cm
-1
 which was identified as the OH functional 
group. A multiplet peak was observed at 3.11 ppm and a singlet at 2.89 ppm which 
were assigned as the peaks of H-6 and O-H respectively on the 
1
H NMR spectrum. 
The doublet, with a coupling constant of 1.2 Hz, present downfield (5.01 ppm), was 
identified as the peak for H-9. The H-10 peak was identified downfield as a triplet 
(4.15-4.12 ppm) with coupling constants of 7.0 and 3.4 Hz. The AB-quartet system of 
the bridge was also identified downfield at 1.11-1.29 ppm. In the 
13
C NMR spectrum, 
the carbon of C-6 shifted to 67.7 ppm as expected as a result of the reduction. The 
peaks of C-3 (212.9 ppm), C-10 (137.4 ppm) and C-9 (134.6 ppm) were identified  
and assigned in the 
13
C NMR spectra. The presence of these peaks (C-3, C-9 and C-
10) indicate that only the carbonyl moiety at C-6 was reduced while the double bond 
and carbonyl moiety of C-9/10 and C-3 respectively, were intact. The physical data of 
compound 3 conformed to the literature (Ito et al., 2007; Salles et al., 2012). 
3.3.4: 2-bromine-3, 6-epoxytricyclo[6.2.1.0
2,7
]undecan-9-one (4) 
3
4
2
5
7
6
89
110
O
11
O
Br
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Synthetic method: To a solution of compound 3 (0.56 g, 3.16 mmol) in 
CH2Cl2 (20 ml) cooled to 0 °C via an external ice-water bath, N-bromosuccinimide 
(0.84 g, 4.74 mmol) was added and stirred for 2 hours. The resulting mixture was 
concentrated in vacuo and purified via silica gel column chromatography using 
hexane:ethyl acetate (1:4) as eluent, yielding the pure compound  as a yellow powder 
(yield: 0.53 g, 94.4%). 
PHYSICAL DATA: 
C11H13BrO2; MW: 257.1 g/mol; Mp.: 72-75 
o
C; IR (ATR; cm
-1
): 3681, 1695, 1411, 
1033, 1184, 711 cm
-1
; 
13
C-NMR (50 MHz, CDCl3) δ (ppm): 203.7 (C-3), 87.5 (C-9), 
75.1 (C-6), 54.8 (C-10), 48.7 (C-2), 48.5 (C-8), 47.8 (C-1), 45.1 (C-7), 42.5 (C-4), 
38.4 (C-11), 34.8 (C-5).
 1
H-NMR (200 MHz, CDCl3) δ (ppm): 4.28-4.35 (m, J = 
7.4/3.8 Hz, 2H, H-6/9), 4.02 (d, J = 3.2 Hz, 1H, H-10), 3.56 (m, 1H, H-2), 3.07-3.14 
(dd, J = 10.2/4.4 Hz, 1H, H-8), 2.61-2.84 (m, 3H, H-1/4), 2.24-2.37 (m, 1H, H-7), 
1.99-2.12 (m, 2H, H-5), 1.06-1.56 (m, 2H, H-11).  
STRUCTURE ELUCIDATION: 
 Several characteristic functional moieties such as the epoxy between C-9 and 
C-6, the carbonyl at C-3 and the bromo functional group at C-10 were used to identify 
the structure. In the infrared spectrum, the carbonyl group is present at 1695 cm
-1
, the 
bromo group present at 3681 cm
-1
, and the epoxy group is present at 1184 cm
-1
. The 
epoxy group connected to C-9 deshielded the carbon resulting in downfield shift on 
both the 
13
C (87.5 ppm) and 
1
H (4.28 ppm) NMR spectra. The physical data 
conformed to the literature (Ito et al., 2007; Salles et al., 2012). 
3.3.5: 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (5) 
3
4
2
5
7
6
89
110
O
N
11
12
13
16
15
17
14
18
 
Synthetic method: Compound 1 (0.52 g, 3.0 mmol) was dissolved in 
tetrahydrofuran (THF, 10 ml). The mixture was cooled to 0 °C via an external ice-
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water bath while being stirred. To the cooled mixture, an equal molar amount of 
benzylamine (0.32 g, 0.33 ml) was added drop-wise over a period of 10 min. The 
mixture was stirred for 1 hour and the concentrated in vacuo to afford a dark oil. The 
oil was dissolved in dry benzene and placed under Dean-Stark conditions for 4 hours. 
The benzene was evaporated in vacuo and the product purified via silica gel column 
chromatography using dichloromethane:ethyl acetate:hexane (1:1:1) as eluent, 
yielding the desired compound  as white crystals (yield: 36 mg, 4.6%). 
PHYSICAL DATA: 
C18H17NO; MW: 263.3 g/mol; Mp.: 115-118 
o
C; IR (ATR; cm
-1
): 3242, 1677, 1580, 
1247, 1033, 722 cm
-1
; HR-ESI ([M+H]
+
, +O): Calcd. 280.1334, exp. 280.1383; 
13
C-
NMR (50 MHz, CDCl3) δ (ppm): 196.7 (C-6), 149.8 (C-3), 136.1 (C-13), 135.8 (C-
4/5), 133.7 (C-9/10), 128.9 (C-14/18), 128.0 (C-15/17), 127.5 (C-16), 107.1 (C-3), 
49.4 (C-12), 48.9 (C-7), 48.1 (C-11), 46.6 (C-1/8), 30.9 (C-2).
 1
H-NMR (200 MHz, 
CDCl3) δ (ppm): 7.12-7.33 (m, 5H, H-14/15/16/17/18), 5.90-6.07 (m, 2H, H-9/10), 
5.49 (d, J = 6.4 Hz, 1H, H-5), 4.11(d, J = 5.4 Hz, 1H, H-4), 3.45 (t, J = 3.6/1.8 Hz, 
1H, H-7), 3.04-3.21 (m, 2H, H-1/8), 1.97-2.14 (m, 3H, H-2/12), 1.46-1.51 (AB-q, J = 
8.8/5.2/1.8 Hz, 2H, H-11). 
STRUCTURE ELUCIDATION: 
Characteristic functional moieties such as the C=N bond, the C=C bond of C-9/10, the 
carbonyl group, the benzyl moiety and the bridge at C-11 were identified to confirm 
this novel open cage-like molecule. In the infrared spectrum, the C=O is present as a 
sharp peak at 1677 cm
-1
, the C=N is observed at 1580 cm
-1
, and the aromatic group is 
present at 3242 cm
-1
. In the 
1
H NMR spectrum, the AB-quartet system of the bridge at 
H-11 (1.46-1.51 ppm), the protons of the aromatic group (7.12-7.33 ppm), and the 
multiplet of H-9/10 (5.90-6.07 ppm) were evident. The 
13
C NMR spectrum revealed 
aromatic peaks (127.5-128.9 ppm) and the C=N (149.8 ppm) moiety were identified. 
The C=C bonds of C-9/10 (133.7 ppm), C-4/5 (135.8 ppm) were identified downfield. 
The molecular ion from the MS confirmed a mass of 280.1334 amu. 
 
 
 
 
 
 
 
 
 
 
SYNTHESIS 
 
46 
 
3.3.6: 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (6) 
3
4
2
5
7
6
89
110
O
NH
11
12
13
16
15
17
14
18
 
Synthetic method: Compound 5 (0.1 g, 0.38 mmol) was dissolved in a mixture 
of MeOH (12 ml) and THF (60 ml). To this solution, NaBH4 (0.03 g, 0.76 mmol) was 
added and stirred for 36 hours at room temperature. The mixture was concentrated in 
vacuo and water (50 ml) was added. The mixture was extracted with CH2Cl2 (3 x 25 
ml). The combined organic layers were washed with water (50 ml) and dried with 
MgSO4. Evaporation of the organic solvents yielded the desired compound as a 
brown-yellow oil (yield: 82 mg, 82%). 
PHYSICAL DATA: 
C18H19NO; MW: 265.3 g/mol; IR (ATR; cm
-1
): 3243, 1677, 1581, 1496, 1246, 1033, 
723 cm
-1
; HR-ESI ([M+H]
+
, +O): Calcd. 282.1493, exp. 282.1539; 
13
C-NMR (50 
MHz, CDCl3) δ (ppm): 207.2  (C-6), 164.1 (C-13), 137.1 (C-4), 136.4 (C-5), 133.1 
(C-9/10), 128.7 (C-14/18), 127.8 (C-15/17), 127.5 (C-16), 66.0 (C-3), 49.8 (C-12), 
48.6 (C-7), 46.7 (C-11), 45.5 (C-1/8), 30.9 (C-2).
 1
H-NMR (200 MHz, CDCl3) δ 
(ppm): 7.22-7.29 (m, 5H, H-14/15/16/17/18), 5.74-6.15 (m, 2H, H-9/10), 5.27 (s, 1H, 
H-3), 4.85 (s, 1H, H-4), 4.17 (d, J = 8 Hz, 1H, H-5), 3.44 (d, 2H, H-12), 3.11 (s, 1H, 
H-8), 2.86 (t, J = 8.8/2.2 Hz, 2H, H-1/7), 2.10-2.23 (m, 2H, H-2 and H-N), 1.81-1.39 
(m, 2H, H-11). 
STRUCTURE ELUCIDATION: 
 Since there are structural similarities between compound 5 and 6, it is 
expected that it spectra should be similar. The difference in the structures of 5 and 6 is 
the reduction of the imine in compound 5 to the amine in compound 6. The amine 
bonds were used to identify this structure. In the infrared spectrum, the N-H is present 
at 1581 cm
-1
. In the 
1
H NMR spectrum, the aromatic protons (7.22-7.29 ppm), the 
proton of H-3 (5.27 ppm) and the proton of N-H bond (2.23 ppm) were evident. In the 
 
 
 
 
SYNTHESIS 
 
47 
 
13
C NMR spectrum, an upfield shift of C-3 (66.0 ppm) was evident. The molecular 
ion from the MS confirmed a mass of 282.1493 amu. 
3.3.7: 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (7) 
3
4
2
5
7
6
89
110
O
N
11
12
13
16
15
17
14
18
 
Synthetic method: Compound 2 (0.3 g, 1.7 mmol) was dissolved in THF (20 
ml). The mixture was cooled to 0 °C with an external ice-water bath with stirring. To 
the cooled mixture, an equal molar amount of benzylamine was added drop-wise over 
a period of 10 min and it was stirred for 1 hour. The mixture was concentrated in 
vacuo to afford a brown oil. The oil was dissolved in dry benzene and placed under 
Dean-Stark conditions for 4 hours. The benzene was evaporated and the crude product 
was purified via silica gel column chromatography using dichloromethane:ethyl 
acetate:hexane (1:3:1) as eluent, yielding compound 7 as a brown oil (yield: 17 mg, 
4.1%). 
PHYSICAL DATA: 
C18H19NO; MW: 265.3 g/mol; IR (ATR; cm
-1
): 3243, 1667, 1580, 1246, 1033, 722 
cm
-1
; HR-ESI ([M+H]
+
, +O): Calcd. 282.1485, exp. 282.1539; 
13
C-NMR (50 MHz, 
CDCl3) δ (ppm): 206.9 (C-6), 142.4 (C-3), 137.7 (C-13), 135.8 (C-9/10), 128.8 (C-
14/18), 128.2 (C-15/17), 127.7 (C-16), 50.0 (C-12), 49.4 (C-7), 48.1 (C-11), 46.7 (C-
1/8), 30.8 (C-5), 28.8 (C-2), 21.2 (C-4). 
1
H-NMR (200 MHz, CDCl3) δ (ppm): 7.23-
7.39 (m, 5H, H-14/15/16/17/18), 7.16 (d, J = 0.8 Hz, 1H, H-9), 6.94 (t, J = 3.4/1.6 Hz, 
1H, H-10), 4.42 (d, J = 3.4 Hz, 2H, H-1/8), 4.09 (t, J = 3.4/1.8 Hz, 1H, H-7), 2.86-
2.99 (m, 1H, H-2), 2.34-2.51 (m, 6H, H-4/5/12),1.41-1.45 (AB-q, J = 8/4.4/2.8/0.8 
Hz, 2H, H-11). 
STRUCTURE ELUCIDATION: 
 Characteristic signals that were identified to confirm compound 7 included; 
the aromatic group, the C=N bond, and the carbonyl group at C-6. In the infrared 
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spectrum, the aromatic hydrogen is present at 3243 cm
-1
, the C=N bond at 1580 cm
-1
, 
and the carbonyl group (C=O) at 1677 cm
-1
. In the 
1
H NMR spectrum, the aromatic 
hydrogens (7.23-7.39 ppm) and AB-quartet system of the bridge at C-11 (1.41-1.45 
ppm) were evident. In the 
13
C NMR spectrum, the aromatic carbons (127.7-128.8 
ppm) and carbonyl group (206.9 ppm) were identified. The molecular ion from the 
MS confirmed a mass of 282.1485 amu. 
3.3.8: 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (8) 
3
4
2
5
7
6
89
110
O
NH
11
12
13
16
15
17
14
18
 
Synthetic method: Compound 7 (80 mg, 0.38 mmol) was dissolved in a 
mixture of MeOH (12 ml) and THF (60 ml).  To the final solution, NaBH4 (0.03 g, 
0.76 mmol) was added and stirred for 36 hours at room temperature. The mixture was 
concentrated in vacuo and water (50 ml) was added. The mixture was extracted with 
CH2Cl2 (3 x 25 ml). The combined organic layers were sequentially washed with 
water (50 ml), aqueous NaHCO3 solution (100 ml) and again with water (50 ml) and 
dried over MgSO4. The organic layer was evaporated, yielding the product as a brown 
oil (yield: 32 mg, 40%). The product was further purified via a silica gel preparative 
chromatography plate using dichloromethane:ethyl acetate:hexane (1:3:1) as eluent, 
yielding the final compound as a brown oil (yield: 1.52 mg, 1.9%). 
PHYSICAL DATA: 
C18H21NO; MW: 267.4 g/mol; 
13
C-NMR (50 MHz, CDCl3) δ (ppm): 207.2 (C-6), 
136.0 (C-13), 135.2 (C-9/10), 128.9 (C-14/18), 128.1 (C-15/17), 127.6 (C-16), 59.5 
(C-3), 51.9 (C-12), 49.8 (C-7), 47.3 (C-11), 46.1 (C-1/8), 39.0 (C-5), 30.9 (C-2), 22.8 
(C-4). 
1
H-NMR (200 MHz, CDCl3) δ (ppm): 7.22 (t, J = 10.4/7.2 Hz, 5H, H-
14/15/16/17/18), 6.10 (s, 2H, H-9/10), 3.99-4.29 (m, 2H, H-12), 3.79 (m, 1H, H-8), 
3.72 (m, 1H, H-3) 3.44 (s, 1H, H-1), 3.09-3.23 (m, 1H, H-7), 2.86-2.99 (m, 2H, H-5), 
1.81-2.44 (m, 4H, H-2/4 and N-H), 1.21-1.45 (AB-q, J = 15/7.4 Hz, 2H, H-11). The 
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NMR, MS and IR spectra of purified compound 8 are not available because of a very 
low yield. 
STRUCTURE ELUCIDATION: 
The NMR spectra outlined for compound 8 were those of the crude product. Further 
purification resulted in low yield and thus could not be elucidated using the MS and 
IR. Although impure, similarities exist between compound 7 and 8. Characteristic 
peaks that were used to identify this structure include; the 
13
C and 
1
H at position 3, the 
N-H moiety, the aromatic hydrogens and the AB-quartet system of the bridge. On the 
1
H NMR spectrum, the aromatic hydrogens (7.22-7.31 ppm) and AB-quartet system 
of the bridge at C-11 (1.21-1.45 ppm) were evident. The hydrogens of the N-H (1.81-
2.44 ppm) and H-3 (3.72 ppm) were identified upfield and downfield, respectively. In 
the 
13
C NMR spectrum, the aromatic carbons (127.6-128.9 ppm) and carbonyl group 
(207.2 ppm) were identified. Due to the reduction of C=N bond, there was a upfield 
shift (59.5 ppm) of C-3 in the 
13
C NMR spectrum. 
3.3.9: 10-(benzylamino)-6, 9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-one (9) 
3
4
2
5
7
6
89
110
O
11
O
NH
12
13
18
17
14
16
15
 
Synthetic method: To a solution of compound 4 (80 mg, 0.31 mmol) in THF 
(5 ml), benzylamine (34 mg, 0.31 mmol) was added. The mixture was placed in a 
microwave reactor and reacted at 150 W, 150 °C and 200 psi for 3 hours. The mixture 
was concentrated in vacuo and purified via silica gel column chromatography using 
dichloromethane:ethyl acetate:hexane (1:1:1) as eluent, yielding compound 9 as a 
brown oil (yield: 30 mg, 34.1%). 
PHYSICAL DATA: 
C18H21NO2; MW: 283.4 g/mol; IR (ATR; cm
-1
): 3366, 1691, 1405 1197, 1023, 684 
cm
-1
; HR-ESI [M+H]
+
: Calcd. 284.1646, exp. 284.1645; 
13
C-NMR (50 MHz, 
CDCl3) δ (ppm): 213.5 (C-3), 131.0 (C-13), 129.7 (C-14/18), 129.2 (C-15/17), 129.0 
(C-16),  81.8 (C-6), 75.6 (C-9), 63.7 (C-8), 49.5 (C-7), 48.7 (C-12), 48.5 (C-2), 42.3 
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(C-10), 40.5 (C-4), 34.8 (C-1), 33.9 (C-5), 25.6 (C-11).
 1
H-NMR (200 MHz, CDCl3) 
δ (ppm): 7.15-7.30 (m, 5H, H-14/15/16/17/18), 4.01 (d, J = 1.8 Hz, 2H, H-12), 3.68 
(s, 1H, H-6), 2.92 (d, J = 5 Hz 1H, H-9), 2.61 (m, 1H, H-10), 1.76-2.61 (m, 9H, H-
1/2/4/5/7/8 and H-N), 1.21-1.45 (dt, J = 14.0/8.8/4.0, 2H, H-11). 
STRUCTURE ELUCIDATION: 
 Several characteristic functional moieties such as the carbonyl group (C=O) at 
C-3, the epoxy group of C-6 and C-9, the N-H (amine bond), the bridge at C-11 and 
the aromatic group were used to identify this structure. On the infrared spectrum, the 
aromatic group is present at 3366 cm
-1
, the C=O at 1691 cm
-1
, the N-H at 1196 cm
-
1
and the epoxy group at 1023 cm
-1
. In the 
1
H NMR spectrum, the double triplet (1.21-
1.45 ppm) of the bridge at C-11, the aromatic hydrogens (7.15-7.30 ppm), the 
hydrogens of the epoxy group at C-6 (3.68 ppm) and C-9 (2.92 ppm) were evident. In 
the 
13
C NMR spectrum, the C=O (213.5 ppm) and the aromatic carbons (129.0-129.7 
ppm) were identified. The molecular ion from the MS confirmed a mass of 284.1646 
amu. 
3.3.10: 10-(benzylamino)-6, 9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-ol (10) 
3
4
2
5
7
6
89
110
OH
11
O
NH
12
13
18
17
14
16
15
 
Synthetic method: Compound 9 (100 mg, 0.3 mmol) was dissolved in a 
mixture of methanol (12 ml) and THF (60 ml). To the mixture, NaBH4 (11 mg, 0.3 
mmol) was added and stirred at room temperature for 1.5 days. The mixture was 
concentrated in vacuo, water (50 ml) was added and the solution was extracted with 
dichloromethane (3 x 25 ml). The combined organic layers were washed with water 
(50 ml) and dried with MgSO4. The organic layer was concentrated in vacuo and the 
product purified via a silica preparative chromatography plate using ethanol:ethyl 
acetate (1:2) as mobile phase. The product was obtained as a brown oil (yield: 30 mg, 
30%). 
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PHYSICAL DATA: 
C18H23NO2; MW: 285.4 g/mol; IR (ATR; cm
-1
): 3356, 1559, 1456, 1052, 700 cm
-1
; 
HR-ESI [M-H]
+
: Calcd. 284.1643, exp. 284.1645; 
13
C-NMR (50 MHz, CDCl3) δ 
(ppm): 136.4 (C-13), 129.3 (C-14/18), 128.6 (C-15/17), 127.9 (C-16), 84.2 (C-6), 
69.8 (C-9), 64.7 (C-3), 50.4 (C-8), 48.8 (C-7), 42.4 (C-12), 40.1 (C-10), 40.0 (C-2), 
33.5 (C-1), 31.9 (C-11), 29.7 (C-5), 27.2 (C-4).
 1
H-NMR (200 MHz, CDCl3) δ 
(ppm): 7.48-7.59 (m, 5H, H-14/15/16/17/18), 4.07 (t, J = 3.6/1.8 Hz, 2H, H-12), 3.61 
(s, 1H, H-O), 3.31 (s, 1H, H-3), 3.14 (s, 3H, H-6/9/10), 2.54 (d, J = 1.6 Hz, 1H, H-8), 
2.18-2.31 (m, 1H, H-7) 1.99 (s, 2H, H-1/2), 1.85-1.92 (m, 4H, H-4/5), 1.47-1.61 (m, 
2H, H-11). 
STRUCTURE ELUCIDATION: 
 In confirming compound 10, the hydroxyl group at C-3 was identified. The 
C=O of compound 9 was reduced to produce the C-OH (compound 10). The infrared 
spectrum shows that the peaks for C=O is absent and the broad peak of C-OH is 
present at 3356 cm
-1
. In the 
1
H NMR spectrum, the aromatic hydrogens (7.48-7.59 
ppm), the hydroxyl hydrogen (3.61 ppm) and the hydrogen at C-3 (3.31 ppm) were 
evident. In the 
13
C NMR spectrum, the aromatic carbons (127.9-129.3 ppm), the 
carbons attached to the epoxy group, and the carbon at C-3 (64.7 ppm) were 
identified. As expected, there was a shift to the right (upfield) in the NMR spectrum 
of compound 10. The molecular ion from the MS confirmed a mass of 284.1643 amu. 
3.4: CONLUSION 
 A total of 10 compounds were successfully synthesised. The structure and 
purity of all except compound 8 were confirmed with IR, MS and NMR analysis. The 
exception of compound 8 was due to low yield obtained during final purification. 
However, the NMR spectrum of the impure compound 8 was analysed for the purpose 
of identification. In future, a larger optimised synthetic procedure needs to be 
conducted in order to synthesise enough material for NMR, MS and IR analysis. 
Of the 10 compounds synthesised, only compound 1 (86%), 3 (82.7%), 4 (94.4%) and 
6 (82%) showed substantial yields. Low to moderate yields were observed with the 
remaining compounds (2, 5, 7, 8, 9, and 10). The low yields observed were due to the 
formation of by-products during synthesis and compound lost during purification. 
Optimisation of the various synthetic techniques developed in this study is required to 
produce final products with substantial yields. 
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The spectra from MS, IR and NMR were used to confirm these novel 
polycyclic cage-like molecules. However, spectra analyses were purely based on 
chemical shifts and literature assignment with the novel compounds (5-10) 
extrapolated from the existing compounds (1-4), thus additional NMR spectral 
analyses, including HSQC, HMBC, COSY, NOESY, DEPT and 2D experiments are 
required to adequately assign signals of synthesised compounds. Further analysis will 
include XRD to unequivocally confirm these novel structures. 
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Figure 3.1: Successfully synthesised compounds for biological evaluation. 
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CHAPTER FOUR 
Biological evaluation 
4.1: Introduction 
The evaluation of calcium flux through NMDA receptors and VGCC was 
conducted, utilising murine synaptoneurosomes. The test model was developed in our 
laboratory and is described in this chapter. This model uses the fluorescent ratiometric 
indicator, Fura-2 AM, and a Synergy™ Mx Monochromator-based fluorescent 
Microplate Reader (figure 4.1) with Gen 5
™ 
data analysis software to measure relative 
changes in intracellular calcium levels after cell membrane depolarisation. This dual 
wavelength ratiometric approach detects excitation of calcium-bound and calcium-
free concentrations at wavelength of 340 nm and 380 nm respectively, and emission at 
510 nm. The ratio of fluorescent intensities, at the two excitations, enables the 
monitoring and quantification of intracellular calcium ions (Bozark et al., 1990; 
Neher, 1995). This approach offers the advantage of internal calibration of calcium 
ions, and obviates the need for experimental correction for photobleaching, sample 
thickness variability and dye concentration (Gee et al., 2000; Hu et al., 2005; 
Kukkonen, 2009). Inevitable problems such as compartmentalisation, incomplete AM 
ester hydrolysis and extrusions may potential arise with the use of Fura-2 AM (Hu et 
al., 2005). The treatment of the synthesised compounds (1-10) in the same manner as 
the control (DMSO only) and reference compounds, with known activities, is capable 
of producing results that indicates the relative change in calcium flux through the  
murine synaptoneuromes. Thus, the influence of the aforementioned problems on the 
results (NMDA receptor and VGCC assays) is negligible. With the described method, 
we envision that the potential mono-inhibition or dual inhibitions of the synthesised 
compounds on NMDA receptors and/or VGCC will be established. All results are 
expressed as percentage of the control. 
 
Figure 4.1: Synergy™ Mx Monochromator-based fluorescent Microplate Reader. 
 
 
 
 
BIOLOGICAL EVALUATION 
 
54 
 
4.2: Imaging experiment using Fura-2 AM 
4.2.1: Materials 
Chemicals used were of analytical grade or spectroscopy grade and were 
purchased from Sigma-Aldrich (UK) and Merch (St. Louis, MO, USA). 
4.2.2: Animals 
The study protocol employed was approved by University of the Western 
Cape Ethical Committee responsible for research on Experimental Animals (SRIRC 
2012/06/13). The rats were sacrificed by decapitation and the brain tissue was 
removed and kept on ice for homogenisation. The homogenised brain tissue was used 
immediately. 
4.2.3: Preparation of synaptoneurosomes 
Wistar rats were decapitated and the whole brain was removed after cerebral 
cortex dissection. The brain was homogenised in 20 ml ice-cold incubation buffer 
(118 mM NaCl; 4.7 mM KCl; 1.18 mM MgCl2; 0.1 mM CaCl2; 20 mM HEPES and 
30.9 mM glucose. pH adjusted to 7.4) using a Teflon glass homogeniser (8 strokes by 
hand). To reduce proteolysis, the homogenate was kept on ice-cold water throughout 
the preparation. The tissue suspension was divided into two polycarbonate tubes and 
centrifuged at 1000 g (Labofuge 20 at 3300 rpm) for 5 minutes at 4 ºC. The 
supernatant was decanted and redistributed in 2-ml aliquots, which were again 
centrifuged at 15000 g (Labofuge 20 at 12500 rpm) for 20 minutes. The supernatant 
was discarded and the pellet re-suspended in sufficient calcium-free buffer (118 mM 
NaCl; 4.7 mM KCl; 1.18 mM MgCl2; 20 mM HEPES and 30.9 mM glucose. pH 
adjusted to 7.4) to obtain a 3 mg/ml protein concentration (protein yield is 
approximately 10 mg per 1 g of tissue).  
4.2.4: General methods 
 Utilising the Synaptoneurosomes isolated from murine brain tissue. Samples 
of the control (DMSO only) and the test compounds, at 100 µM, were prepared. The 
samples were screened using a Synergy™ Mx Monochromator-based fluorescent 
Microplate Reader (BioTek
®
, Germany) connected to Gen 5
™ 
data analysis software. 
Analyses from these data were used to evaluate the influence of tested compounds on 
calcium flux. The methods used in preparation of murine synaptoneurosomes and 
solution, and techniques, for experimental measurement of fluorescent intensities 
were similar to published studies (Stout & Reynolds, 1999; Geldenhuys et al., 2007; 
Joubert et al., 2011). All data analysis and calculations were performed using Prism 
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6.02
®
 (GraphPhad, Sorrento Valley, CA). Data in bar charts are expressed in % values 
of the control with each bar representing the mean ± SEM. Statistical analysis was 
carried out using the Student Newman Keuls multiple range test. The level of 
significance was accepted at p < 0.05. 
4.2.5: General procedure for loading Fura-2 AM and incubating test 
compounds 
Experiments were carried out at 37 °C and the fluorescent intensities measured 
using a Synergy™ Mx Monochromator-based Microplate Reader with Gen 5™ 
analytical software. Fura-2 AM (1 mg/ml in DMSO) was added to the re-suspended 
tissue to make a final concentration of 5 μM. The synaptoneurosomes were then 
incubated at 37 °C for 30 minutes. To prevent hydrolytic degradation of Fura-2 AM, 
the synaptoneurosomal-Fura-2 AM were protected from light. The incubated tissue 
was centrifuged at 7000 g for 5 minutes and the supernatant was discarded to remove 
all extracellular Fura-2 AM. The pellets were re-suspended in CaCl2 containing buffer 
(118 mM NaCl; 4.7 mM KCl; 1.18 mM MgCl2; 2 mM CaCl2; 20 mM HEPES and 
30.9 mM glucose, pH adjusted to 7.4) to obtain a final concentration of 0.6 mg/ml 
(protected from light). A 10 μM stock solution of the test compounds were prepared. 
2 μl of the individual stock solutions were diluted with synaptoneurosomal-Fura-2 
AM suspension (0.2 ml) in 96-well plates to give 100 μM concentrations of the 
compounds. DMSO was used as the control to eliminate the possible influence of 
DMSO in the experiment.  
4.2.6: NMDA/glycine-mediated NMDA receptor
 
stimulation 
The wavelengths selected for calcium-bound and calcium-free excitations 
were 340 nm and 380 nm respectively, and both emitted light as fluorescence at 510 
nm. An automated fluorescent plate reader with the optics position set at the top and 
sensitivity set at 100 was used. The runtime was 5 minutes with 48 milliseconds 
intervals to obtain a total of 626 readings per run. The procedure was initiated and 
kept at 37 °C. At 10 seconds into the reading, 10 μl (225 μl/sec) of stimulation 
solution (0.1 mM NMDA; 0.1 mM glycine; 1.4 mM CaCl2, pH adjusted to 7.4) was 
injected into each well plate, using an automated dispenser, to activate the NMDA 
receptor channels for the purpose of calcium influx. Calcium flux is determined by the 
fluorescence intensity produced through stimulation. An increase in fluorescence 
intensity after NMDA/glycine-induced stimulation represents 100% calcium influx as 
indicated by control (DMSO only). A decrease in fluorescent intensity, relative to the 
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control, with reference compounds and synthesised compounds indicate the inhibitory 
activity exhibited by test compounds. The difference in fluorescent intensity as a 
result of these inhibitions, after neuronal membrane depolarization, is expressed in 
percentage. The experiments were performed in triplicate using fresh 
synaptoneurosomes prepared on the same day. This was repeated three times. 
4.2.7: KCl-mediated VGCC depolarisation 
The wavelengths selected for calcium-bound and calcium-free excitations 
were 340 nm and 380 nm respectively, and both emitted light as fluorescence at 510 
nm. An automated fluorescent plate reader with the optics position set at the top and 
sensitivity set at 100 was used. The runtime was 5 minutes with 48 milliseconds 
intervals to obtain a total of 626 readings per run. The procedure was initiated and 
kept at 37 °C. At 10 seconds into the reading, 10 μl (225 μl/sec) of KCl (140 mM) 
depolarisation solution (5.4 mM NaCl; 140 mM KCl; 10 mM NaHCO3; 0.6 mM 
KH2PO4; 0.6 mM Na2HPO4.10H20; 0.9 mM MgSO4; 1.4 mM CaCl2; 20 mM HEPES 
and 5.5 mM glucose, pH adjusted to 7.4) was injected into each well plate, using an 
automated dispenser, to depolarise the voltage-gated calcium channels for the purpose 
of calcium influx activation. The KCl-induced increase in fluorescence intensity 
represents 100% calcium influx through depolarised membrane as indicated by the 
control (DMSO only). A decrease in fluorescent intensity, relative to the control, with 
reference and synthesised compounds indicate the inhibitory activity exhibited by test 
compounds. The difference in fluorescent intensity reflects the extent of inhibition, 
which is expressed in percentage. The experiments were performed in triplicate using 
fresh synaptoneurosomes prepared on the same day. This was repeated three times. 
4.2.8: Statistical analysis 
All data analysis, graphs and calculation were performed using the Prism 6.02
®
 
(GraphPhad, Sorrento Valley, CA). Data in bar charts are expressed in % values of the 
control with each bar representing the mean ± SEM. Statistical analysis was carried 
out using the Student Newman Keuls multiple range test. The level of significance 
was accepted at p < 0.05. Bonferroni’s multiple comparison, one way analysis of 
variance ANOVA was performed on selected data to indicate significant differences 
between test compounds (p < 0.05 was considered to be a statistically significant 
difference). 
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4.3:  Results and discussion 
4.3.1: NMDA receptor calcium flux inhibition  
In this NMDA receptor inhibition study, the relative change in calcium flux, as 
indicated by change in fluorescence intensity, through synaptoneuromes after 
NMDA/glycine-induced receptor stimulation was used to evaluate the NMDA 
receptor inhibition of the reference compounds (memantine, MK-801 and NGP1-01) 
and tricycloundecane derivatives (1-10). The ratiometric fluorescent indicator, Fura-2 
AM, was used to monitor these changes. The results, average inhibition of three 
experiments on different murine synaptoneurosomes (table 4.1), represent the 
inhibitory effects, at 100 µM, and were relative to the control. The control (DMSO 
only) represented 100% calcium flux (figure 4.2). The reference compounds were 
MK-801, NGP1-01 and memantine.  
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Figure 4.2: Screening of test compounds (100 μM, n = 9) for inhibition of NMDA-mediated 
calcium flux in murine synaptoneurosomes. Each bar denotes mean percentage of control 
values ± SEM. Abbreviations are: Control (C), memantine (M), MK-801 (MK) and NGP1-01 
(NG).  Statistical analysis was performed on raw data. The asterisks indicate significance of 
inhibitory effect of test compounds [(*) p < 0.1. (**) p < 0.05. (***) p < 0.001] when 
compared to the control (100%). 
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Table 4.1: Calcium influx inhibition (NMDA receptor) by tested compounds. 
Compound Structure Calcium flux inhibition 
(100 µM) (%) 
€
Control  0 
Memantine 
NH2
CH3
CH3  
57.90
*
 
MK-801 
NH
CH3
 
97.47
***
 
NGP1-01 
O
NH
 
57.20
*
 
1 
O
O
 
33.33 
2 
O
O
 
78.00
**
 
3 
OH
O
 
96.07
***
 
4 O
O
Br
 
48.33 
5 
O
N
 
0.33 
6 
O
NH
 
10.53 
7 
O
N
 
100.00
***
 
8 
O
NH
 
11.10 
9 
O
O
NH
 
38.20 
10 
OH
O
NH
 
33.33 
€
Control = DMSO only       *p < 0.1   **p < 0.05   ***p < 0.001 
As anticipated, MK-801, NGP1-01 and memantine showed significant 
inhibitory activity (figure 4.1) of 97.47%, 57.20% and 57.90%, respectively. MK-801 
is a known uncompetitive NMDA receptor antagonist with high affinity for the PCP 
binding site located within the channel (Black et al., 1996). Antagonist such as MK-
801 is trapped in the receptor channel and recovery for this trap-blocked state is 
generally slow thus producing a very long duration of action (Geldenhuys et al., 
2007). This accounts for the high inhibitory activity when compared to both 
memantine and NGP1-01, polycyclic cage molecules. Although memantine and 
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NGP1-01 are potent NMDA receptor blockers, affinities toward the receptor channel 
are considered low due to the faster rate of blocking (Hao et al., 2008). The inhibitory 
effect of NGP1-01 was slightly less than memantine. 
The synthesised compounds (1-10), evaluated at 100 µM, were subjected to 
the same treatment as the control (DMSO only) and the reference compounds. Of the 
10 compounds, only compound 2, 3 and 7 showed significant NMDA inhibitory 
activity (p < 0.05) of 78.00%, 96.07% and 100%, respectively when compared to the 
control (figure 4.2). The remaining compounds (1, 4, 5, 6, 8, 9 and 10) showed weak 
to moderate NMDA inhibitory activity in the range between 0.33% and 48.33%. 
Compound 1 (33.33%) showed moderate inhibitory activity at 100 µM. 
However, significant increase in NMDA receptor inhibition was observed with 
compound 2 (78.00%) and 3 (96.07%). The inhibitory activity of compound 2 
exceeded that of the reference compounds, memantine and NGP1-01, while 
compound 3 showed inhibition similar to MK-801. The increased inhibitory activity 
of compound 2 compared to compound 1 suggests that the reduction of the C=C bond 
in the cyclohexene aromatic ring improved interaction with the NMDA receptor 
channel. It can be argued that the presence of the C=C bond offers rigidity to the open 
polycyclic cage (compound 1; Ito et al., 2007; Etzkorn et al., 2009) thus restricting 
movement that enable it to conform to the receptor pocket which would be required to 
effectively antagonise the NMDA receptor ion channel. Further reduction of one of 
the carbonyl moieties to a hydroxyl moiety (compound 3) resulted in a significant 
increase in NMDA antagonism similar to MK-801. The increased activity can be 
attributed to improved hydrogen bonding interaction with the NMDA receptor pocket 
mediated by the hydroxyl group (Nagata et al., 1995; Gitto et al., 2014). However, a 
weaker inhibitory activity was observed with the more conformational restricted 
polycyclic cage molecule (compound 4). The increased lipophilicity incurred and/or 
halo-substitution (Br) at position C-10 may also have contributed to the reduced 
inhibitory activity. 
Of the novel tricycloundecyl amine and imine derivatives, only compound 7 
(100%) showed significant NMDA inhibitory activity. The activity observed 
exceeded the reference compounds. However, the activity of compound 7 needs to be 
tested at lower concentrations to proof that its activity is in the same range as MK-
801. This would eliminate false positive NMDA receptor inhibitory activity. It should 
be noted that compound 7 is a benzylimine derivative of compound 2, therefore the 
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improved activity was expected as suggested by Geldenhuys et al. 2007. It is thus 
suggested that the benzyl ring improves the NMDA receptor interaction and therefore 
increases NMDA antagonism for this group of compounds. It can be argued that the 
benzyl ring undergoes a π-π type aromatic interaction with (an) aromatic acid(s) 
located at the entrance of the NMDA receptor channel. Such interaction would allow 
the molecule to be anchored in such a way that the cage can descend into the channel 
lumen and enable optimal NMDA inhibitory activity (Geldenhuys et al., 2007). 
Unfortunately, the reduction of the C=N (compound 7) bond to C-N (compound 8) 
abolished the inhibitory activity and it is suggested that the drastic reduced activity 
observed with compound 8 was due to: (1) uncontrolled flexibility that is beyond 
acceptable NMDA receptor conformation, and (2) steric hindrance offered by the 
receptor channels. Compound 5 (0.33%), 6 (10.53%), 9 (38.20%) and 10 (33.33%) 
showed weak to moderate NMDA inhibition. 
4.3.2: VGCC calcium flux inhibition 
Tricycloundecane derivatives were evaluated for VGCC inhibition by 
measuring calcium influx into murine synaptoneurosomes using the fluorescent 
technique as described. The ratiometric fluorescent indicator, Fura-2 AM, was used to 
monitor the change in intracellular calcium ion concentration after depolarisation of 
the VGCC with a high KCl (140 mM) concentration solution. The ratio of the calcium 
bound and unbound fluorescent intensities of test compounds, relative to a control 
(100% influx), gives an estimate of the degree of inhibition produced by the reference 
compounds and the synthesised (1-10) compounds. In this study, the reference 
compounds were nimodipine, amantadine and NGP1-01. Nimodipine is a 
commercially available dihydropyridine l-type calcium channel blocker used to treat 
vascular disorders. When compared to other calcium blockers, it passes the blood 
brain barrier more readily and binds specifically with high affinity to l-type calcium 
channels in the brain functionally antagonising steady state calcium load upon long or 
weak depolarization. Thus, nimodipine is a good candidate to evaluate the 
neuroprotection offered by VGCC antagonism (Marchetti & Usai, 1996; Bailey et al., 
2013). NGP1-01 and its derivatives have been shown to block VGCC and offer 
neuroprotection to neurons in the brain. Although amantadine and its derivatives have 
neuroprotective properties, they only inhibit NMDA receptors but not VGCC. 
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Table 4.2: Calcium influx inhibition (VGCC) by tested compounds. 
Compound Structure Calcium flux inhibition 
(100 µM) (%) 
€
Control  0 
Amantadine 
NH2
 
2.57 
Nimodipine CH3 O
CH3 O
N
H
NO2
CH3 CH3
O
O
CH3
O
 
90.19
***
 
NGP1-01 
O
NH
 
25.63
**
 
1 
O
O
 
11.97 
2 
O
O
 
0.67 
3 
OH
O
 
3.50 
4 O
O
Br
 
3.00 
5 
O
N
 
1.90 
6 
O
NH
 
34.03
*
 
7 
O
N
 
38.07
**
 
8 
O
NH
 
6.67 
9 
O
O
NH
 
14.33 
10 
OH
O
NH
 
40.33
*
 
€
Control = DMSO only       *p < 0.1   **p < 0.05   ***p < 0.001 
The results in table 4.2 show the average inhibition of three experiments on 
different synaptoneurosomal preparations at 100 µM. From the calcium flux data 
(figure 4.3), nimodipine showed very high VGCC inhibition indicated by little or no 
increase in fluorescence ratio after depolarisation. Nimodipine exhibited statistically 
significant VGCC inhibitory activity in synaptoneurosomes at a concentration of 100 
μM (90.19%) when compared to the KCl control treated synaptoneurosomes.  
At the same concentration, compounds 6 (34.03%), 7 (38.07%), and 10 
(40.33%) exhibited better VGCC inhibitions than NGP1-01 (25.63%) with significant 
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activity (p < 0.05) when compared to the control (DMSO). Compound 1, 2, 3, 4, 5, 8 
and 9 exhibited weak calcium antagonism between 1.90% and 14.33%. Although 
some of the synthesised compounds showed significant activity, none had inhibitory 
activity compared to nimodipine. 
C A N
N
G 1 2 3 4 5 6 7 8 9 1 0
0
5 0
1 0 0
T e s t  C o m p o u n d s
%
 C
a
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iu
m
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x
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**
*
** *
Figure 4.3: Screening of test compounds (100 μM, n = 9) for inhibition of VGCC-mediated 
calcium flux in murine synaptoneurosomes. Each bar denotes mean percentage of the control 
values ± SEM. Abbreviations are: Control (C), amantadine (A), nimodipine (N) and NGP1-01 
(NG).  Statistical analysis was performed on raw data. The asterisks indicate significance of 
inhibitory effect of test compounds [(*) p < 0.1. (**) p < 0.05. (***) p < 0.001] when 
compared to the control (100%). 
There was no or little activity observed with the basic polycyclic structures (1-
4) while some of the novel polycyclic amine and imine compounds (6, 7 and 10) 
showed significant VGCC inhibitory activity. This suggests the importance of 
benzylamine and benzylimine group for activity. Of the novel polycyclic amines 
evaluated, compound 6, 7 and 10 showed improved activities when compared to 
NGP1-01, an established VGCC blockers with neuroprotective properties. An 
increased activity was observed when the carbonyl group of compound 9 was reduced 
to a hydroxyl group (10). It can be argued that the presence of the hydroxyl group 
provides better interaction with the binding sites of the voltage-gated calcium 
channels. The influence of the unsaturated (C=C and C=N) bonds were noticeable 
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from the comparison of compounds 5, 6, 7 and 8. Compound 6 and 7 showed 
significant VGCC activity that exceeded the activity of NGP1-01. It can be argued 
that the reduction of one of the unsaturated bonds of compound 5, as seen in 
compound 6, offers flexibility to the structures and thus a better fit in the channel-
binding site. The reduction of compound of the imine in 7 to the amine, as 
demonstrated in compound 8, reduced VGCC activity. This is possibly due to a 
change in the orientation of compound 8 into a configuration unsuitable for VGCC 
activity. 
4.4: Conclusion 
The procedure developed to evaluate the synthesised compounds, with 
reference to literature, was able to indicate potential NMDA receptor and VGCC 
inhibitory activities for the test compounds when compared to known active reference 
standards. This procedure, using the fluorescent ratiometric calcium indicator, Fura-2 
AM, monitored the relative change in calcium influx affected by the test compounds. 
The potential NMDA receptor and VGCC inhibitions of the synthesised compounds 
were established and their structure-activity relationships discussed using the newly 
developed method.  
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CHAPTER FIVE 
Conclusion 
5.1: General 
The progression of neurodegenerative disorders are mediated by various 
degenerative processes. This has been the major challenge for the treatment thereof. 
The challenges lie not only in the multi-interrelated degenerative processes, but also 
the development of drug-like molecules that halt degenerative processes or facilitate 
neuronal regeneration. There is thus a need for neuroprotective agents with 
multifunctional activity with the potential to cure these disorders. Although several 
mechanisms have been proposed and structures designed, a standard mechanism for 
neuroprotection has not been established and no single agent has yet been successful 
in clinical trials. Of the known mechanisms, excitotoxic effects via disruption in 
calcium homeostasis on neuronal cells are prominent. The increase in intracellular 
calcium, or excessive accumulation thereof in neuronal cells, results in cellular 
dysfunction and subsequently neuronal cell death. Two major pathways, namely the 
VGCC and NMDA receptors, have been demonstrated in the literature to be 
responsible for this excessive calcium influx and ultimately excitotoxicity. The 
activation can either be direct or via coupled-protein activation. Targeting these 
pathways could be of therapeutic value in the design and development of molecular 
functionalities with dual- or multi-functional activities that attenuate the degenerative 
process. Although inhibiting these channels and receptors could proof valuable, it is 
important to maintain calcium-mediated physiological functions. With this in mind, 
we embarked on synthesising several open cages and rearranged polycyclic moieties 
structurally similar to NGP1-01, a known NMDA receptor and VGCC blocker, and 
evaluated their inhibitory potential on these channels. 
5.2: Chemistry 
 Open polycyclic compounds (1-8) and endocyclic ether structures (9-10) with 
a number of distinct functionalities were successfully synthesised (figure 5.1). The 
lead molecule, an endo form of tricycloundeca-4,9-diene-3,6-dione (1), has high 
symmetry that allows for facile selective reactions at one or both carbonyl groups by 
means of classical and non-classical reagents (Ito et al., 2007). The lead molecule was 
synthesised using the cycloaddition reaction described by Ito et al. (2007). This 
procedure yielded compound 1 as the endo isomer after recrystallisation from hexane 
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to produce pure yellow crystals (86%). In the presence of zinc and glacial acetic acid, 
the lead molecule was selectively reduced to yield 2 (50.3%). Compound 2 was 
further reduced with NaBH4 at the carbonyl group present in position 3 and compound 
3 was obtained in 82.7% yield. The treatment of 3 with N-bromosuccinimide resulted 
in a closed ring bromoether derivative (4) in substantial yield (94.4%). The structures 
of these compounds (1, 2, 3 and 4) were confirmed on the basis of their respective 
NMR and IR spectra and served as precursors for the novel tricycloundecane 
derivatives.  
O
O
O
O
OH
O
O
O
Br
O
N
O
NH
O
N
O
NH
O
O
NH
OH
O
NH
1 2 3 4
5
6
7
8
9 10
Figure 5.1: Structures of tricycloundecane derivatives (1-10). 
Novel compounds (5 and 7) were obtained through amination of the precursors 
with an equal molar amount of benzylamine in THF. The selective protonation, at 0 
ºC, of one of the carbonyl groups (1 and 2) made the structures prone to nucleophilic 
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attack by the free electron pair on the nitrogen of the primary amine found in 
benzylamine. The nucleophilic attack resulted in the formation of carbinolamine 
intermediates which was dehydrated under Dean-Stark conditions to obtain the imines 
5 (4.6%) and 7 (4.1%), respectively. The reduction of compound 5 and 7 using 
NaBH4 as a reducing agent yielded compound 6 (82%) and 8 (1.9%), respectively. 
The formation of compound 9 (34.1%) required the use microwave irradiation at 150 
ºC, 150 W and 200 psi. Under these extreme conditions, the bromide group of 
compound 4, as opposed to the carbonyl group, reacted with the primary amine on the 
benzylamine to yield the desired compound (9). This suggest that compound 4 might 
have a configuration that shielded the carbonyl group, thus minimising interaction at 
this site and facilitating SN2 nucleophilic substitution at the bromide group. 
Compound 10 (30%) was obtained by the reduction of the carbonyl group of 9 using 
NaBH4. The spectra from MS, IR and NMR were used to confirm these novel 
polycyclic cage-like molecules. 
5.3: Biological activity 
 In this study, the NMDA receptor and VGCC inhibitory activities of the 
successfully synthesised polycyclic cage molecules were evaluated using a fluorescent 
ratiometric calcium indicating technique. In the NMDA/glycine-mediated calcium 
influx assay, significant inhibitory activities compared to NGP1-01 and memantine 
were recorded for compound 2 and 3. Interestingly, the benzylimine derivative (7) of 
compound 2 demonstrated the highest inhibitory activity. Compound 7 showed 
inhibitory activity in the same range as MK-801, a known potent NMDA receptor 
antagonist. The NMDA receptor inhibitory activities of the remaining compounds (1, 
4, 5, 6, 8, 9 and 10) were in the low to moderate range. These activities suggested and 
supported the important role of hydrogen bond and hydrophobic interactions at the 
NMDA receptor site as reported in the literature (Leeson et al., 1990; Kroemer et al., 
1998; Gitto et al., 2014). It was also evident that structural modifications significantly 
influenced the activities of this group of compounds. A significant increase in activity 
was noted from compound 2 to 3 and the activity dramatically improved by formation 
of the benzylimine derivative (7). However, reduction of the imine to an amine 
abolished NMDA receptor inhibitory activity. In the KCl-mediated calcium influx 
assay which was used to demonstrate VGCC inhibitory activity, low activities were 
observed with compound 1, 2, 3, 4, 5, 8 and 9. Significant inhibitory activities were 
recorded for compound 6, 7 and 10. The increased activities exceeded that of NGP1-
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01, but none matched the activity of nimodipine. The reduction of compound 9 to an 
alcohol derivative (10) resulted in a significant increase in VGCC inhibitory activity. 
The increased hydrophilicity of 10 appeared to offer better interaction with VGCC 
and enhanced inhibitory activity. Significant increase in VGCC inhibitory activities 
were also observed following the conversion of the benzylimine (5) to benzylamine 
(6). The formation of 6 offered less rigidity to the cage-like molecule and improved 
the activity thereof. The activity of 7 diminished after reduction to its amine (8).  
This study confirms the possibility of VGCC inhibition (6 and 10), NMDA 
receptors inhibition (2 and 3) and dual-inhibition (7) for the respective compounds. 
Compound 6, 7 and 10 were the novel tricycloundecane derivatives while structure 2 
and 3 were previously described (Ito et al., 2007) but their NMDA receptor and/or 
VGCC activities were not explored. Mono-inhibition (NMDA receptor or VGCC) or 
dual-inhibition (NMDA receptor and VGCC) have been proven to attenuate calcium 
influx through these major pathways. This offers protection to neuronal cells where 
death is caused by excessive calcium influx mediated by over-activation of NMDA 
receptor channels and VGCC. We have thus established that open and endocyclic 
ether containing polycyclic cage derivatives, structurally similar to NGP1-01 and 
MK-801, exhibit potential neuroprotective properties by inhibition of NMDA 
receptors and/or VGCC. These polycyclic cage-like molecules could be further 
explored or used as lead structures for the development of compounds that may be 
potential treatment options for neurodegenerative disorders mediated by 
excitotoxicity. 
5.4: Conclusion and further recommendations  
A series of tricycloundecane derivatives were successfully synthesised and 
their potential inhibitory activities on NMDA receptors and VGCC were 
demonstrated. The tricycloundecane derivatives (compound 2, 3, 6, 7 and 10) can thus 
be considered as potential neuroprotective agents, a notion supported by the results, 
and may serve as new lead polycyclic cages for the development of active 
pharmaceutical agents.  
 From the results obtained, it is recommended that a more comprehensive 
series be synthesised to increase our understanding of the structure-activity 
relationships and mechanism of interaction with the putative binding sites of this 
group of compounds. Further multifunctional neuroprotective activity of these 
compounds is also yet to be confirmed and future investigation on the sigma receptor 
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could provide valuable information to establish the potential of these compounds as 
neuroprotective agents with a broad-spectrum of activities for the treatment of 
neurodegenerative disorders. Blood-brain permeability studies, kinetic studies and 
cytotoxicity assays of these compounds are also recommended.  
The biological assay described has demonstrated potential neuroprotective 
properties of the synthesised compound via NMDA receptor and VGCC antagonism 
thus it is a useful tool for preliminary calcium flux inhibitory screening of prospective 
lead structures. Albeit, it did not provide information about the true blocking actions, 
bindings, or affinities of the synthesised compounds to the receptors and channels. 
Electrophysiological studies are required to further elaborate on the mechanism of 
action of the tricycloundecane derivatives. Further development of these structures 
should also be conducted to elaborate on their true potential NMDA receptor and 
VGCC inhibitions and neuroprotective abilities. 
Although these compounds demonstrated significant VGCC activity (6, 7 and 
10) and NMDA activity (2, 3 and 7) compared to NGP1-01 and memantine, their 
clinical use and safety in humans still needs to be proven. Further in vitro and in vivo 
studies are thus recommended to establish the true neuroprotective potential of these 
polycyclic molecules.  
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APPENDIX 1 
SPECTRAL DATA: 
INFRARED, MASS AND 
NUCLEAR MAGNETIC RESONANCE 
SPECTRA 
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Spectrum 1: 
1
H NMR of tricyclo[6.2.1.0
2,7
]undeca-4,9-diene-3,6-dione (1). 
Spectrum 2:
 13
C NMR of tricyclo[6.2.1.0
2,7
]undeca-4,9-diene-3,6-dione (1).  
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Spectrum 3: Infrared of tricyclo[6.2.1.0
2,7
]undeca-4,9-diene-3,6-dione (1).  
Spectrum 4:
 1
H NMR of tricyclo[6.2.1.0
2,7
]undec-9-ene-3,6-dione (2). 
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Spectrum 5:
 13
C NMR of tricyclo[6.2.1.0
2,7
]undec-9-ene-3,6-dione (2). 
Spectrum 6: Infrared of tricyclo[6.2.1.0
2,7
]undec-9-ene-3,6-dione (2). 
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Spectrum 7: 
1
H NMR of 6-hydroxytricyclo[6.2.1.0
2,7
]undec-9-en-3-one (3). 
Spectrum 8:
 13
C NMR of 6-hydroxytricyclo[6.2.1.0
2,7
]undec-9-en-3-one (3). 
 
 
 
 
APPENDIX 
 
92 
 
Spectrum 9: Infrared spectrum of 6-hydroxytricyclo[6.2.1.0
2,7
]undec-9-en-3-one (3). 
Spectrum 10: 
1
H NMR of 2-bromine-3, 6-epoxytricyclo[6.2.1.0
2,7
]undecan-9-one (4). 
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Spectrum 11:
 13
C NMR of 2-bromine-3, 6-epoxytricyclo[6.2.1.0
2,7
]undecan-9-one (4). 
Spectrum 12: Infrared spectrum 2-bromine-3, 6-epoxytricyclo[6.2.1.0
2,7
]undecan-9-one (4). 
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Spectrum 13: 
1
H NMR of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (5). 
Spectrum 14:
 13
C NMR of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (5). 
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Spectrum 15: MS of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (5). 
Spectrum 16: infrared of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (5). 
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Spectrum 17: 
1
H NMR of 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (6). 
 
Spectrum 18: 
 13
C NMR of 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one (6). 
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Spectrum 19: MS of 3-(benzylamino)tricyclo[6.2.1.0
2,7]
undeca-4,9-dien-6-one (6). 
 
Spectrum 20: Infrared spectrum of 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undeca-4,9-dien-6-one 
(6).  
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Spectrum 21: 
1
H NMR of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (7). 
Spectrum 22: 
13
C NMR of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (7). 
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Spectrum 23: MS of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (7). 
 
Spectrum 24: Infrared spectrum of 3-(benzylimino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (7). 
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Spectrum 25: 
1
H NMR of Impure 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (8). 
 
Spectrum 26: 
13
C NMR of Impure 3-(benzylamino)tricyclo[6.2.1.0
2,7
]undec-9-en-6-one (8). 
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Spectrum 25: 
1
H NMR of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7]
undecan-3-one (9). 
Spectrum 26: 
13
C NMR of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7]
undecan-3-one (9). 
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Spectrum 27: MS of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-one (9). 
Spectrum 28: Infrared spectrum of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-
one (9). 
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Spectrum 29: 
1
H NMR of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-ol (10). 
 
Spectrum 30: 
13
C NMR of 10-(benzylamino)-6, 9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-ol (10). 
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Spectrum 31: MS of 10-(benzylamino)-6, 9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-ol (10). 
 
Spectrum 32: Infrared spectrum of 10-(benzylamino)-6,9-epoxytricyclo[6.2.1.0
2,7
]undecan-3-
ol (10). 
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